Since 1965 there have been more than 980 pharmacogenetic reviews--most suggesting that we are on the verge of offering individualized drug therapy to everyone. Whereas genomics has succeeded in the identification of numerous genes related to complex diseases, extending these findings to individualized drug therapy will be extremely difficult to achieve in the foreseeable future. Drug treatment outcome represents a complex phenotype, encoded by hundreds of genes and affected by many environmental factors; therefore, there is always a gradient in drug response. Phenosstyping with probe drugs has not succeeded, due to overlapping substrate specificities not only of drugmetabolizing enzymes but also transporters, receptors, ion channels, transcription factors and other unknown drug targets; drug-drug interactions, enzyme induction and inhibition, and multiple (enzyme, transporter, 2nd-messenger, signal transduction) pathways also present enormous problems. Genotyping to predict drug disposition, efficacy, toxicity and clinical outcome has been proposed, but success of genotyping in individualized drug therapy presently appears unlikely, because of many shortcomings (frequency of DNA variant sites, ethnic differences, admixture) and complexities (plasticity of the genome, sizes and locations of haplotype blocks). Genomics is an important tool in basic research; yet, it is unrealistic to include genotyping within the realm of tests available to the practicing clinician. The same can be said about transcriptomics, which relies on available sources (tumors, biopsies, excreta). The newly emerging fields of metabolomics and proteomics might complement pharmaco-genomics in offering solutions to anticipate and decrease individual risk for adverse drug reactions in each individual patient; tests based on these approaches are not expected to become available to the practicing clinician, however, for at least the next 5-10 years.
Recent analysis of the human and mouse genomes brought to light a large number of conserved non-genic sequences (CNGs) (Dermitzakis et al. Nature 420: 578, 2002 , and Science 302: 1033 . Although their conservation is high enough to strongly support their functionality, the actual role of these sequences remains unknown. We have performed three different sets of analyses to dissect the properties of CNGs. First, we have compared 1628 CNGs and 950 conserved exons of Hsa21 between human, mouse and dog. This analysis reveals that selective constraints of CNGs do not depend on proximity to genes or position on the chromosome and suggests a more global role of CNGs than the conventional models of interaction (e.g. regulatory) with genes in cis. We have also performed a whole genome analysis of CNGs and have correlated their spatial distribution with the one of exons. It is evident that there is a highly significant negative correlation between the CNG and exon density in the human genome. This further supports the independence of CNGs from their genic environment and highlights the need for innovative methodologies to dissect their functional properties. Finally, we have explored levels of nucleotide variation of 95 CNGs in 10 French Europeans and 10 West Africans and compared them with levels of variation in exons, introns, regulatory regions and random intergenic sequences in the same individuals and previously published data. Preliminary analysis shows that the levels of polymorphism within most CNGs (average heterozygosity: ? = 0.0002) are well below the human genome average and very similar to exonic sequences. We also observe two main modes in the levels of variation: one of highly suppressed variation (~80% of CNGs) and one of high variation CNGs (~20% of CNGs). Furthermore, CNGs with sufficient amounts of variation exhibit an excess of rare polymorphisms indicative of strong negative selection. Our results together with those from our previous studies argue that CNGs are genomic elements that may participate in known as well as unknown functions of the human genome. In addition, the high level of rare nucleotide variation in otherwise highly conserved CNGs suggests that a substantial amount of functional variation in the human genome may be harboured in CNGs.
The International HapMap Project and its Impact on Pharmacogenomics
Phillips M.* Director of Pharmacogenomics, Genome Quebec, Montreal, Canada A combination of genetic variations and environmental factors defines an individual's responsiveness to drugs (efficacy and adverse reactions). Genetic variations in genes encoding proteins involved in drug metabolism, transport, and response are of increasing importance for selecting the optimal dosing and drug selection for a patient. Although any two unrelated people share about 99.9% of their DNA sequences, the remaining 0.1% is important because these are the markers that account for an individual's risk for adverse drug reactions or susceptibility to complex diseases. Discovering the DNA sequence variants that contribute to common disease risk offers one of the best opportunities for understanding the complex causes of disease in humans. The goal of the International HapMap Project is to develop a haplotype map of the human genome, the HapMap, which will describe the common patterns of human DNA sequence variation. The International HapMap Project is working towards a genome-wide haplotype map with a SNP placed every 5 kb. This information will aid researchers searching for the genetic factors that affect health, disease, and responses to drugs and the environment. The Project is a partnership among scientists and funding agencies in Canada, China, Japan, the U.K., Nigeria, and the U.S. The strategy is to assay many of the approximately 10 million single nucleotide polymorphisms (SNPs) commonly found in the human genome, and determine which 200,000 to 1 million SNPs can be used as "tags" to identify the common haplotype patterns present in individuals. Haplotypes are proving to be more informative than individual SNPs on their own when performing genotype/phenotype correlations. By assaying tag SNPs, researchers should be able to discover genetic associations to disease, adverse drug reactions and other phenotypes on a genome-wide scale in a cost effective and meaningful way. We are currently using this information for the development of genetic panels to be used in pharmacogenomic and disease risk assessment studies.
SESSION: CARDIOVASCULAR DISEASES: PREDISPOSITION GENES AND POLYMORPHISMS

Significant Polymorphisms in the Stanislas Cohort
Visvikis-Siest S.* Inserm U.525, University Henri Poincaré Nancy 1, Nancy, France Although hundreds of polymorphous candidate genes are known, only a small percentage of genetic variability in cardio-vascular risk factors was explained. New candidate genes must be searched for. Besides, considering the partial failure of strategies to prevent cardio-vascular diseases, based on the reduction of classical risk factors, it is urgent to search for and study further intermediate phenotypes and particularly the products of candidates genes. The general message of our presentation is how to contribute to the knowledge of the mechanisms involved in the pathologies of the cardio-vascular system through an integrated approach, from genotype to biological phenotype, and taking into account environmental factors. We will focus more particularly on coding genes for inflammatory molecules, without neglecting biological systems which have a well-established part in atherosclerosis: lipid metabolism and blood pressure regulation. Many studies were carried out on the Stanislas Cohort, a longitudinal study started in 1993 made up of 1006 French families supposed to be healthy and from homogeneous origin. However, each study was based on a particular subsample. Given that familial correlations have been clearly demonstrated to be important, it would be interesting to describe the family resemblance in a single population. This familial resemblance would be selected from well-defined criteria, in order to validate and to gather previous results. Selected variables are lipids, blood pressure, adhesive and inflammatory molecules. Therefore, 190 families composed of two parents and at least one children coming at the first (1994) and the second (1999) health examinations have been selected. The members of these families were not under medication. The first part of this talk consists in describing this sample of the Stanislas Cohort. Secondly, we established the family resemblances of the selected variables by the maximum likelihood method 1 after the standardization of the data by multiple regression adjusted for age, sex, BMI, alcohol and tobacco consumption. The genetic variance has then been estimated by variance analysis 2, 3 . Finally, we will present the major genes involved in this genetic variance.
Muscle-dedicated DNA Chips for Cardiovascular Diseases
Léger J.J.* Inserm U533, IFR 26, Ouest Genopole, Nantes, France Sequencing of the whole human genome made global analyses of transcriptomal (proteomic) activities within any cell or tissue possible. Subcollections of striated muscle-dedicated genes had been selected either through subtractive hybridization experiments or differential screening of pangenomic chips between normal and diseased tissues, and from literature information. The gene selection obtained within a consortium of eight different laboratories corresponded to about 5,000 genes preferentially/differentially expressed in skeletal/cardiac muscles, among the putative 35,000 genes possibly identified in the human genome. 50 mer oligonucleotides, representing the 5,000 genes, were spotted in quadruplicate on glass slides. Replicate hybridizations of such musclededicated chips with 20,000 spots for each biological sample, issued from at least a double RNA extraction, deliver multiple experimental expression values for each sample. Such metrological requirements applied on a well-defined collection of genes involved in striated muscle functioning are key elements to assess the inherent biological and experimental variability of such high-throughput experiments like DNA chips.
The in-house made muscle-dedicated chips were used in different cardiovascular programs like chronic atrial fibrillation (AF) and end-stage heart failure (HF). AF is the most common sustained cardiac arrhythmia in humans, while HF is the main cause of mortality in developed countries. We performed transcriptomal analysis on right atrial appendages from 11 patients with chronic AF and underlying valvular disease and from 7 patients with valvular disease only. In parallel we performed transcriptomal analysis on left and right ventricles of transplanted hearts of 47 patients with endstage HF. All AF patients were individually compared to a sex-and age-matched control group, while all HF patients were compared to a composite control group composed of samples from each HF patient. AF-specific and HF-specific transcriptomal remodeling affecting different functional pathways involving hundreds of genes were then comparatively identified. We will present and discuss our results, which will clearly lead to a better understanding of the comparable, and different remodeling mechanisms involved in the pathophysiology of AF and HF.
The Use of Transgenic Mice in Studying Polymorphisms Related to Cardiovascular Diseases
Hofker M.*, Wouters K., Sverdlov R., van Gorp P., de Winther M., van Bilsen M.
Departments of Molecular Biology and Physiology, CARIM, Maastricht University, Maastricht, The Netherlands
The use of transgenic mice has been pivotal in understanding the molecular genetic mechanism of atherosclerosis, the major cause of cardiovascular disease. Instrumental for this breakthrough has been the development of the apolipoprotein E (APOE) knockout mouse, which shows a marked increase in atherogenic lipoproteins and is highly susceptible to atherosclerosis. This "sensitized" mouse strain has been invaluable to investigate the role of additional genes in atherosclerosis, such as inflammatory genes, lipid modifying enzymes and transcription factors. A large number of such genes have been modified in mice, and crossed onto the APOE knockout mouse stain, providing excellent examples of the effect of gene-gene interactions in a complex genetic disorder. In man, mutations in APOE are the main cause of type III hyperlipidemia. The phenotype of the disease is highly variable due to genetic and environmental factors. Similarly, mice carrying the different mutant alleles of APOE, such as APOE2 and APOE3Leiden, show marked increased plasma lipoprotein levels. In addition, the APOE-mutant mice are highly susceptible to additional genetic factors and environmental effects, such as dietary components and newly developed pharmacological molecules. Two approaches have been used to further detect additional genes modulating the phenotype of APOE transgenic mice. 1) Through mouse genetics, crosses have been made using different inbred mouse strains to detect novel genetic loci controlling the metabolism of plasma lipids. 2) Genomic analysis with micro-arrays has been used to evaluate the effects of diet and drugs in the APOE-mutant mice. These approaches show that the APOE-mutant mice are good models to study genetic mechanisms of type III hyperlipidemia and for testing the effect of drugs and diets.
Inflammation and Cell Lipid Metabolism Regulation by the Interaction of Fatty Acids with Nuclear Receptors
Masana L.*
Unitat de Recerca de Lípids i Arteriosclerosi-IRCIS-Red de centros RCMN (C03/08), Universitat Rovira i Virgili, Spain
Chronic inflammation is a key feature of atherogenesis. Peroxisome proliferator activated receptor g (PPAR g) activation has shown net antiatherosclerotic effects in atherosclerotic animal models and in clinical studies with high-risk patients. It is known that PPAR agonists have anti-inflammatory effects by reducing proinflammatory cytokine production but their mechanism of action is still under study.
Extensively oxidized low-density lipoprotein (oxLDL) inhibits macrophage cytokine secretion and has been pointed out as a source of PPARg biological ligands. We have identified two functional PPAR response elements (PPRE) in the human TNF-α promoter sequence with high similarity to the previously described consensus sequence. These data are the first evidence linking PPAR directly to the modulation of inflammatory responses providing a new mechanism of action of PPAR agonists that could benefit the treatment of inflammatory related diseases. We have also studied the effects of 2,4-decadienal, an oxidative end product of fatty acids that accumulates in oxLDL, on PPARγ activity. Preliminary data suggest that 2,4-decadienal may be an endogenous PPARγ agonist ligand in the atherosclerotic plaque. Because fatty acids are considered the natural ligands for PPARγ we have analyzed the effects of several saturated, polyunsaturated and monounsaturated fatty acids in the regulation of cholesterol homeostasis in macrophages. PUFA and other FA in minor extension upregulate CD36 and ABCA1 genes via PPARγ. The combination of these effects could lead to an increase of abnormal lipoprotein particles uptake and an HDL dependent cholesterol depletion. Fatty acids and some of their oxidation products, as aldehydes, via nuclear receptors, could play a role in the inflammatory reaction and cholesterol accumulation that takes place in the arteriosclerotic plaque.
Phenotypic and Genetic Dissection of Metabolic Syndrome: The GEMS Project
Waterworth D., Barter P., Bersot T., Cohen J., Farrer L., Kesaniemi A., Grundy S., McPherson R., Mahley R., Waeber G., Middleton L., Wyszinsky D., Mooser V.* Glaxo Smith Kline, King of Prussia, USA Metabolic syndrome, a clustering of atherogenic conditions including hypertension, dyslipidemia, obesity and glucose intolerance/diabetes, affects around one third of the adult population in industrialized countries. The goal of the multinational GEMS project is to better understand the architecture and genetic basis of metabolic syndrome. A total of 3,243 members from 504 families (including 1,672 individuals with atherogenic dyslipidemia, as defined by the concomitant presence of low HDL cholesterol and high triglycerides in plasma), >900 unrelated cases and >1300 discordant controls (high HDL cholesterol and low triglycerides) have been recruited in GEMS. Detailed phenotypic analysis established that the definition used in GEMS for cases strongly correlates with the criteria proposed as 'gold standards' (ATP-III) for metabolic syndrome. Moreover, it was demonstrated by one of the GEMS investigators (G. Waeber) that atherogenic dyslipidemia is closely associated with endothelial dysfunction, increased intima-media-thickness of peripheral arteries and glucose intolerance. An extensive analysis of plasma biomarkers has been performed, and principal component analysis is being used to delineate the relationships between them and generate informative composite phenotypes. Preliminary analysis from the whole genome scan performed on GEMS identified a series of linkage peaks.
The Additive Effect of Coexistence more than one "Susceptibility Gene" Alleles on Development of Obesity, Insulin Resistance and Hypertension Wybranska I.*, Malczewska-Malec M., Dembinska-Kiec A., Golabek-Leszczynska I., Jabrocka A., Kiec-Wilk B., Partyka L., Hartwich J., Bodzioch M.
Department of Clinical Biochemistry, The Jagiellonian University Medical College, Krakow, Poland Several quantitative trait loci have been associated with different features of the metabolic syndrome and the genetic susceptibility have been suggested for multiple polymorphisms in a number candidate of genes. PPAR-γ 2 , LPL, FABP-1, β 2 AR, β 3 AR, DRD 2 , MCR-3, MCR-4, UCP-1, HSP-70, FOX-C2; TNF-α, apoCIII and apoE gene polymorphisms were analyzed in our study. Several of these genes are involved in direct nutrient interactions, suggesting potential targets for diet modification therapies and the dietary fat is a single most important environmental factor that can modify the impact of the metabolic syndrome. The results of standardized meal (80 g of total fat) on the triglycerides, free fatty acids, insulin and leptin within 8 hours were analyzed. The 250 members of 90 obese families (South Poland) participated in the study. Moreover, because the family members tend to share a similar environment, therefore in our study we can also shown the existence of strong genegene interactions that highly influenced the phenotype. For example, the phenotype of the group which characterize existence of two selected homozygous polymorphism's at risk compared to group of the protective genotype demonstrated strong difference in the several components of metabolic syndrome (parameters of obesity, insulin resistance and hypertension). Moreover the additive effect of coexistence more than one "susceptibility gene" alleles on the development of metabolic syndrome was also observed. The gene-gene interaction highlight also the importance of studies examining the effects of common genetic polymorphisms within the context of dietary factors. Different genetic backgrounds of various geographic, ethnic or social populations justify the undertaking of large screening programs aimed at the characterization of the genetic variability as it may lead to the development of the targeted nutritional interventions. This work was supported by Ministry of Informatics and Science grants 4P05D08424; 4P05D01016; 501/Pkl/113/L, 501/Kl/563/L, W130/P/L.
The cholesterol transporter protein, ATP Binding Cassette A1 (ABCA1), and the transcriptional repressor, Zinc Finger Protein 202 (ZNF202), are involved in HDL cholesterol homeostasis. Whether genetic variation in ABCA1 and ZNF202 contributes to HDL cholesterol levels and risk of ischemic heart disease in the general population is presently unclear. To address this question, we screened all coding and regulatory regions in 200 individuals with extreme HDL cholesterol levels (1% lowest for age and gender, n=100, and 1% highest for age and gender, n=100), selected from the Copenhagen City Heart Study (n=9,259). The entire cohort was subsequently genotyped for all nonsynonymous SNPs. Disease causing mutations in the ABCA1 and ZNF202 genes are much more common in the general population than previously assumed. Functional SNPs segregate differently in extreme HDL groups both as single sites and as haplotypes and these same SNPs affect HDL cholesterol levels in the entire cohort as single sites and as combined genotypes. In conclusion, both mutations and SNPs in the ABCA1 and ZNF202 genes contribute to HDL cholesterol levels in the general population. Systematic screening of individuals with extreme phenotypes is suggested as an approach for selecting functional SNPs for large-scale genotyping. There is evidence that variations in genes involved in lipoprotein metabolism can affect the magnitude of response to lipid-lowering dietary and drug treatments aimed at reducing risk for cardiovascular disease. We have found that such genetic effects can be more readily discerned by analyses of LDL subclasses than by standard lipid and lipoprotein measurements. In particular, a common genetically-influenced atherogenic lipoprotein phenotype characterized by a predominance of small, dense LDL particles is associated with greater change in levels and distributions of specific LDL subclasses in response to treatment with a low-fat diet and an HMG CoA reductase inhibitor. Known polymorphisms in three candidate genes associated with this phenotype (LDLR, APOAV, CETP) were found to predict increased response of specific LDL subclasses to a low-fat diet (p<0.02 to <0.002). A more comprehensive search for genetic polymorphisms predictive of lipoprotein response to diet and drugs has taken the approach of identifying common SNP haplotypes in candidate genes involved in pathways that influence hepatic cholesterol metabolism and plasma lipoprotein transport. We have found that approximately twice as many haplotypes are identified by sequencing of exons, introns, 1/5 kb upstream and 2.5 kb downstream than by sequencing of exons only. Haplotypes with >10% prevalence were identified in 13 candidate genes in 24 European-Americans and 23 African-Americans. For LDLR in European-Americans, 30 individuals haplotypes that clustered into 5 major groups were tagged with 11 of 70 SNPs with minor allele frequency>10%. One of these SNPs was significantly associated with a diet-induced shift from larger to smaller LDL species (p=0.01, n=310). Therefore perturbation of lipoprotein metabolism by diet and drug therapies can identify polymorphisms in candidate genes that can be further tested for their biological and clinical significance.
Familial Hypercholesterolemia in Europe
Cardiovascular Genomics -Update 2004
Winkelmann B.R.* Cooperation Unit Pharmacogenomics/Applied Genomics, University of Heidelberg, Germany Cardiovascular genomics is the application of genomic techniques to the research of cardiovascular disease, as pharmacogenomics is such application to the study of drug response. The complex genetic cardiovascular traits (i.e. hypertension, stroke, myocardial infarction) are the result of an interaction of genetic variability with environmental stimuli. The idea is to identify causative disease genes, new markers of disease pathways, or genetic markers/genomic patterns of predictive of disease activity or of drug response at the DNA level ("genotyping", "linkage analysis or genome scans", "DNA methylation"), at the mRNA level ("gene expression") or at the protein level ("proteomics"):
DNA level: the study of single gene variants ("SNPs") generates genetic markers for intermediate biochemical phenotypes (low/high activities of enzymes, receptors etc.), but is generally not good enough to predict a complex trait (the "more distant" clinical phenotype). A somewhat more sophisticated approach is the use groups of genetic variants along the same chromosome ("tagged haplotypes"), that carry evolutionary information more closely linked to a complex disease. The methylation pattern of DNA is an important factor that controls transcription and gene expression. Methylation patterns may today be directly analyzed with biochips and used as a diagnostic tool for disease susceptibility. RNA level: techniques have matured to selectively knockout the expression of genes by introducing double-stranded interfering RNA (RNAi), and microarrays are available that fully cover all human genes (the human "transcriptome"). At the protein level, the challenge is to automate the global detection of all proteins in a biologic matrix. Due to the many log-fold wider range in low-and high-abundance proteins (i.e. their concentration) as compared to gene expression activity and their molecular diversity, proteomics (or peptidomics for proteins of a size up to ~20 kiloDalton) is still in its infancy in 2004. Genomic applications rely on a sound and thoughtful application of bioinformatics and statistics. Microarray experiments, for example, need thorough statistical planning in order to define sample size and the expected false positive report probability. This update will report about the application of such genomic techniques with respect to the common cardiovascular diseases.
Pharmacogenomics and the Therapeutic Response to Statins in Hypercholesterolemia
Carrié A.* 1,2 , Lagarde J.P. The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) constitute the most efficacious class of drugs in lowering low-density lipoprotein cholesterol levels (LDL-C), and equally in reducing cardiovascular morbi-mortality. However, large-scale clinical trials have demonstrated significant inter-individual variability in response to statin (LDL-C reduction intensity, adverse muscular effects). Numerous studies have focused on the identification of genetic determinants that may contribute to such inter-individual variability. Genetic polymorphisms may modulate drug response through a range of mechanisms. To date, pharmacogenetic studies of statin response have focused on genes implicated in disease causality and have led to identification of single nucleotide polymorphisms (SNPs) in key genes of lipid metabolism including CETP, ApoE, ApoAI, ABCA1 and ABCG5/G8. By comparison, little is known of variability in genes which may directly influence statin response through pharmacokinetic or pharmacodynamic interactions. Indeed key genes implicated in the pharmacological action of statins, such as HMG-CoA reductase and Cyp3A4, have been screened for polymorphisms associated with variability in drug response, but significant findings are lacking. Among genes which code for proteins interacting directly with statins, the organic anion transporting polypeptide-C gene (OATP-C), now referred as SLCO1B for Solute Carrier Organic Anion Transporter Family, member 1B1, presents as an excellent candidate gene for genetically-determined modulation. OATP-C is responsible for the hepatocellular uptake of statins. Recently, we have undertaken a study to evaluate the contribution of SNPs in the OATP-C coding region to inter-individual variability in response to treatment with Fluvastatin (80 mg/day) in 420 hypercholesterolemic subjects. Our findings demonstrate that OATP-C is intimately involved in the pharmacological action of statins in humans, and that a common OATP-C polymorphism appears to be functionally implicated in the inter-individual variability in response to Fluvastatin. As statins are efficacious in reducing cardiovascular events, genetic heterogeneity in OATP-C may equally represent a key cardiovascular risk factor.
Searching for SNP Profiles for Pharmaco-genetics of Hypertension
Syvänen A.C. Single nucleotide polymorphisms (SNPs) may be useful as markers for predicting genetically determined differences between individuals in response to drug treatment. Hypertension is a multifactorial trait for which various medical treatments are available. Selection of antihypertensive treatment for the patients is usually based on trial-and-error. SNP profiles that would be predictive of individual drug response would be useful as tools for selecting the optimal antihypertensive treatment for each patient. We have developed a microarray-based genotyping system that uses "minisequencing" single nucleotide primer extension for multiplex genotyping of SNPs. The "array-of-arrays" format of our system allows parallel genotyping of up to 200 SNPs in 80 samples per standard microscope slide (1) . We have applied the system for genotyping a panel of 74 SNPs in 25 genes encoding proteins involved in blood pressure regulating pathways (2) . These 74 SNPs were genotyped in hypertensive individuals from the SILVHIA trial (3) , that had been treated with either the angiotensin II type 1 receptor blocker irbesartan (n=48) or the β1-adrenergic receptor blocker atenolol (n=49) as monotherapy for 12 weeks. The aim of our study was to identify SNP profiles that would detect differences between patients in their response to treatment with these two drugs. Using multiple stepwise regression analysis of the whole data set, comprising about 7000 genotypes, we were able to identify profiles of four or five SNP genotypes that explain approximately 50% of the variation in systolic and diastolic blood pressure reduction as a result of treatment with the two drugs (2) . Moreover, analysis of variance of 30 individual SNP genotypes in seven genes from the renin-angiotensin-aldosterone system (RAAS) identified two SNPs in the angiotensinogen gene that were associated to a reduction in systolic blood pressure upon treatment with atenolol. No SNP appeared to be related to the blood pressure response among patients treated with irbesartan (4) . We also explored 20 SNPs in eight genes encoding components of lipid metabolism for their ability to predict response to antihypertensive treatment. We found that a SNP in the apolipoprotein B gene was related to the reduction in systolic blood pressure during treatment with irbesartan, but not upon atenolol treatment. Another SNP in the low density lipoprotein receptor gene predicted the change in systolic blood pressure in the atenolol group only. These results imply a potential role of lipids in blood pressure control. We conclude that although the SILVHIA trial involved a limited number of patients, our study highlights the potential of SNP genotyping by microarray technology as a tool for pharmacogenetics of hypertension. Heart failure is associated with a high morbidity and mortality, with a major socio-economic impact. Although caused by heterogeneous cardiac diseases, the genetic background of heart failure has been recently studied in both monogenic and multifactorial diseases such as dilated cardiomyopathy (DCM). This has led to a better understanding of the underlying mechanisms that promote the development and progression of these diseases. Some genetic polymorphisms of the renin-angiotensin system, or of the beta-adrenoreceptor system, were thus associated with the exercise capacity and the survival of the patients with heart failure due to idiopathic DCM or to coronary artery disease. Some data also suggest interactions between some of these genetic polymorphisms and the benefit of pharmacological treatment, such as beta-blockers or angiotensin converting enzyme inhibitors. The variability in drug response may therefore originate not only from genes involved in the metabolism of these drugs but also from genes encoding their biochemical targets, such as receptors. Although very preliminary, these data are promising and might be the first step towards the application of pharmacogenetics in heart failure. This is of paramount importance as the medical treatment of heart failure is characterized by the need for polypharmacy. (2) . IGF2 loss of imprinting is associated with an increased incidence of cancer (3) , and Beckwith-Weidemann syndrome in children conceived by in vitro fertilization (4) . We have now demonstrated in mice that early postnatal dietary methyl deficiency, and even exposure to a nutritionally complete synthetic diet, high in fat but low in fiber, causes biallelic expression of the oncogene, Igf2. Using viable yellow agouti (A vy ) mice, which harbor a retrotransposon in the agouti gene, we have also shown that maternal dietary methyl donor supplementation during pregnancy alters coat color of the offspring via increased CpG methylation at the A vy locus rather than by genetic mutation (5) . This epigenetic change also reduces the susceptibility of the offspring to obesity, diabetes, and cancer-a clear example of "nature via nurture." Thus, we are not only what we eat, but also potentially what our mother ate when we were in the womb. Our findings provide the first evidence that epigenetic alterations of transposons and imprinted genes can directly link environmental conditions during early development to the etiology of adult diseases. Further understanding these associations should make possible the development of early-life nutritional interventions or corrective therapies aimed at preventing chronic human diseases. (Supported by the NIH grants CA25951 and ES08823, AstraZeneca Pharmaceuticals and the Dannon Institute)
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SESSION: NUTRIGENOMICS (ECOGENOMICS)
The Omega-6/Omega-3 Essential Fatty Acid Ratio and Gene Expression Simopoulos A.P.* The Center for Genetics, Nutrition and Health, Washington, DC, USA Several sources of information suggest that human beings evolved on a diet with a ratio of omega-6 to omega-3 essential fatty acids (EFA) of ~1 whereas in Western diets the ratio is 15/1-16.7/1. Western diets are deficient in omega-3 fatty acids, and have excessive amounts of omega-6 fatty acids compared with the diet on which human beings evolved and their genetic patterns were established. Excessive amounts of omega-6 polyunsaturated fatty acids (PUFA) and a very high omega-6/omega-3 ratio, as is found in today's Western diets, promote the pathogenesis of many diseases, including cardiovascular disease, cancer, and inflammatory and autoimmune diseases, whereas increased levels of omega-3 PUFA (a lower omega-6/omega-3 ratio), exert suppressive effects. In the secondary prevention of cardiovascular disease, a ratio of 4/1 was associated with a 70% decrease in total mortality. A ratio of 2.5/1 reduced rectal cell proliferation in patients with colorectal cancer, whereas a ratio of 4/1 with the same amount of omega-3 PUFA had no effect. The lower omega-6/omega-3 ratio in women with breast cancer was associated with decreased risk. A ratio of 2-3/1 suppressed inflammation in patients with rheumatoid arthritis, and a ratio of 5/1 had a beneficial effect on patients with asthma, whereas a ratio of 10/1 had adverse consequences. These studies indicate that the optimal ratio may vary with the disease under consideration. This is consistent with the fact that chronic diseases are multigenic and multifactorial. Therefore, it is quite possible that the therapeutic dose of omega-3 fatty acids will depend on the degree of severity of disease resulting from the genetic predisposition. A balance between the omega-6 and omega-3 fatty acids is a more physiologic state in terms of gene expression, prostaglandin and leukotriene metabolism, tumor necrosis factor (TNF) and interleukin-1 (IL-1) and IL-6 production. In designing clinical intervention studies, genetic variation should be taken into consideration, since the level of cytokines is genetically determined and the dose of omega-3 fatty acids needed to suppress the pro-inflammatory state varies with the phenotype. Alcohol use is widespread and some drinkers encounter problems as a result. The nature, duration and seriousness of these problems varies and there is strong evidence that the risk of alcohol dependence, at least, is affected by genetic susceptibility. This evidence is based on familial clustering, twin studies, and adoption studies, and has led to several large projects aimed at localising and characterising the genes and alleles which contribute to variation in susceptibility. Results so far indicate that susceptibility resides partly in genes affecting alcohol metabolism (ADH, ALDH) and partly in genes affecting sensitivity to alcohol's effects (ALDH, GABA receptors). Genes affecting personality and comorbid psychiatric conditions also play a role, but have not yet been identified at the molecular level. More generally, it is important to distinguish between alcohol dependence, alcohol intake, and alcohol-related organ damage, and to characterise the genes acting upon each of these. Among the beneficial effects of alcohol, cardiovascular risk is decreased for moderate drinkers, and similarly this reduction may be greater in some people than others because of variation in their genotypes. Our studies have focused on establishing the role of genes by twin studies, assessing candidate genes for associations with dependence, and measuring the biochemical or metabolic changes produced by alcohol use. We have shown significant effects of ADH1B variation on alcohol intake and dependence, but have so far been unable to confirm others' reports of dopamine receptor or serotonin transporter gene effects. The work on biological markers has revealed significant genetic effects on variation in GGT, AST, ALT and CDT. Current studies are based on more extensive linkage and association tests for alcohol dependence. We have recently commenced studies aimed at identifying genes which determine whether, and to what extent, excessive drinkers develop liver function test abnormalities.
Alcohol and Gene Interactions
A-204C Polymorphism in Cholesterol 7alpha-hydroxylase and Cholesterol Responsiveness to the Dietary Changes
Hubacek J.A.*, Kovar J., Pitha J., Skodova Z., Poledne R.
IKEM, CEM, Prague 4, Czech Republic
The relationship between dietary composition and plasma lipids is to some extent genetically determined. We have evaluated the influence of -204A>C variation in the gene for cholesterol 7alpha-hydroxylase (CYP-7A1) on plasma cholesterol levels in 131 males for whom dietary composition markedly changed and total cholesterol decreased (from 6.21±1.31 mmol/l in 1988 to 5.43±1.06 mmol/l in 1996) over an 8 year follow-up study and in eleven nonobese and normolipidemic young men homozygous for either -204A (n=5) or -204C (n=6) allele, consuming for three weeks high-fat high cholesterol (HF) diet and for another three weeks isocaloric low-fat low-cholesterol (LF) diet in cross-over design.The CYP-7A1 -204A>C polymorphism was strongly associated with a decrease in plasma total cholesterol (AA -0.38±0.20 mmol/l, AC -0.65±0.08 mmol/l, CC -1.33±mmol/l, p=0.01) over the 8 year time period in population. In six -204CC homozygotes the concentration of LDL-C was 32% higher on HF diet than on LF diet (2.03±0.30 vs. 1.67±0.42 mmol/l, p<0.01); on the contrary, there was no statistical significant difference in LDL-C in five -204AA homozygotes (HF vs. LF diet: 1.85±0.56 vs. 2.39±0.73 mmol/l). Variation in the CYP-7A1 gene affected the response to dietary change and this effect was seen in a both substudies. -204CC homozygotes showed the greatest change while cholesterol levels in -204AA homozygotes did not respond significantly. We conclude that variation in the CYP-7A1 gene may play an important role in an individual's sensitivity to dietary composition. Environmental factors are known to play a role in many common diseases that also display some familial aggregation suggesting-but not proving-the existence of genetic factors. Such genetic factors may be difficult to evidence if they interact with the environmental factors involved. In this study, we show that such an interaction can be detected by investigating the degree of familial aggregation according to the exposure, not only of relatives, but also of the probands. Indeed, in case of gene-environment interaction, the distribution of genotypes of affected individuals, and consequently the risk in relatives, is dependent on their exposure. We derived the formulae for calculating the risks in sibs according to the exposure of probands and sibs for various values of exposure frequency (fE), susceptibility allele A frequency (p), relative risk due to exposure alone Re, relative risks due to genotypes Aa and AA respectively (RG1 and RG2), and interaction coefficients I1 and I2. We found that the ratio R of risks in sibs when the proband is exposed and not exposed was a good indicator of the interaction effect. As expected, this ratio increases with RG1 and RG2, and also with fE. It was usually higher when gene frequency was set to 0.1 than 0.5. It increased also as RE, RG1 and RG2 increased and was higher under recessive than dominant models. For instance, for fE=0.5, p=0.1, a modest effect of exposure alone (rE=2), no effect of genotype alone (RG1= RG2=1), and a strong interaction effect in homozygotes AA (I2=50), the expected R ratio is 3.37, the marginal relative risk due to exposure is 2.98 and the marginal relative risk in sibs is 2.18. We computed the power of the test comparing the risks in sibs according to the proband exposure in various situations for samples of 300 and 1000 affected individuals. We found that the power was dependent on the ratio R, but also on the model parameters. We concluded that this test was valuable for diseases with moderate familial aggregation, only when the role of the exposure has been clearly evidenced. Celiac disease (CD) is a complex disease of the small intestine induced by gluten. CD is common with a prevalence of ~1:200 in Western populations. A major known susceptibility locus for celiac disease (CD) is the HLA DQ locus. However, the genetic contribution of this region is limited tõ 40%, so non-HLA genes must also be involved in the disease etiology. To unravel novel aspects of disease pathogenesis, we use a functional genomics approach in which we combine genomewide scanning in sibpair families, expression profiling of intestinal biopsies, and bioinformatics for data integration. we use both genetic studies in families and gene expression profiling of duodenal biopsies. A genomewide screen in 101 affected sibpairs identified significant linkage to chromosome 19p13.1. Association studies in matching cohorts of 400 case and controls revealed significant association of single nucleotide polymorphisms (SNPs) spanning some 150 kb, and encompassing a limited number of genes. The associated SNPs combine into a single haplotype that appears more frequently in cases versus controls. In addition, cDNA microarrays were used to compare gene expression profiles of duodenal biopsies from celiac disease patients with villous atrophy and control individuals with normal biopsies. We identified 109 genes that differed significantly (p<0.001) in expression levels between patients and controls. A large number of these genes have functions in proliferation and differentiation pathways and might be important for proper development of crypt-villous units. Alterations in these pathways may lead to the characteristic crypt hyperplasia and villous atrophy seen in celiac disease. We are currently performing extensive functional studies on a number of attractive genes. Interestingly, the linkage region on 19p13.1 contains 8 genes that show differential expression. Since our microarrays only represent ~50% of all known human genes we are currently using complementary methods to investigate the expression pattern of all the genes in the region associated to CD. We expect that the investigation of gene expression data can assist in selecting candidate genes from linkage regions. Furthermore, expression data will point to the molecular pathways involved in disease pathogenesis.
A Functional-genetics Approach to Unravel Molecular Pathways in Celiac Disease
Physiogenomics and the Response to Exercise
Ruano G.* GENOMAS, Hartford, USA Physiogenomics integrates genotypic and phenotypic measures to analyze variability among individuals within a population. In physiogenomics, genotypes and physiological or clinical phenotypes are analyzed to discover statistical associations to environmental responses in individuals similarly exposed or challenged, to exercise, diet or drugs. Variability in a genomic marker among individuals that tracks with the variability in the quantitative response establishes associations and possible mechanistic links with specific genes. Our strategy is "predict response and intervene", quite distinctive from pure gene discovery for disease diagnosis. We call the diagnostic markers derived from physiogenomics "physiotypes". Physiotypes are predictors incorporating haplotypes from various genes, baseline physiological and clinical information and demographic data. Physiotypes are thus multigenetic in nature, and also include clinical information routinely gathered in medical care Physiotypes are multimodular, and each individual module is derived from whether a significant association is found by univariate testing of the respective end point. The overall operational features of physiotypes are specificity and sensitivity each of 80% or more. While each component has individual characteristics, physiotypes reflect combined features of the various modules. Physiogenomics research is a collaboration of Genomas with Dr. Paul D. Thompson of Hartford Hospital. This research has correlated the exercise responses as measured by various variable outcomes with the variability of selected candidate genes. We tested 120 healthy individuals for fasting lipids and other measures before and after 6 months of supervised aerobic exercise training. Small dense LDL particles are atherogenic. We therefore analyzed lipoprotein particle subpopulations in our subjects. Response to exercise was extremely variable with roughly half the individuals demonstrating improvements (lowering) and the other half undesired increases, with a mean percentage change of only -5%, essentially null, but with a range extending from -40%, a substantial decrease to +20%. We discovered a physiotype predictive of the LDL exercise response. This physiotype involved an apolipoprotein gene and two baseline physiological measurements. When translated into a clinical tool, physiotypes could be useful for the individualization of exercise programs to effect desired changes in lipid profiles of individuals.
Folic Acid Intake and of MTHFR Polymorphism in Egyptian Mothers of Children with Down Syndrome
Meguid N.A. The incidence of Down syndrome in Egypt is 1/750 live births. Recent reports linking Down syndrome (DS) to maternal polymorphisms at the methylenetetrahydrofolate reductase (MTHFR) gene locus have generated great interest. It was suggested that 677C→T polymorphism in MTHFR gene may predispose to aberrant DNA methylation and increased risk of meiotic nondisjunction and that abnormal folate and methyl metabolism are associated with the risk of Down syndrome. The present study included 30 mothers with their affected outcomes and 30 control mothers. The aim of this work is to investigate the frequency of C677T MTHFR gene polymorphism in mothers with DS children as a risk factor for nondisjunction. All mothers were subjected to complete medical and nutritional history with special emphasis on folate intake through food or oral supplementation, estimation of blood homocysteine level, and study of MTHFR gene mutation at site 677 by PCR amplification and Hinf1 enzyme digestion. The results of detailed nutritional history indicated that folic acid intake from food and from vitamin supplements was significantly lower (below the Recommended Daily Allowance) in the group of mothers with DS children compared to control mothers (P<0.01) using Student T-test. Blood homocysteine was normal in both control and DS mothers. MTHFR analysis showed absence of polymorphism at 677 sites in both mothers with DS children and control mothers. These results suggest that reduced folate intake, without polymorphisms in the folate pathway, may be sufficient to increase the risk of having a child with D.S. Our results are emphasizing that MTHFR C677T mutation, unlike earlier studies, is not a remarkable genetic polymorphism among Egyptian females with or without DS children. Therefore, other gene loci in MTHFR gene as well as other genes encoding folate biosynthetic pathway enzymes should be studied. Sufficient folate intake and supplementation is an important preventive strategy in overcoming the risk of nondisjunction. Homocysteine was not found to be a sensitive biomarker for folate deficiency in young mothers with DS children. The small intestine is the primordial site for the transport of dietary fats. After the digestive phase, the lipolytic products are absorbed by the enterocytes and subsequently packaged for their secretion as chylomicrons. Translocation of the lipids from the intestinal lumen to the cytosol and subsequently to the endoplasmic reticulum is the first step of this complex process and involves fatty acid binding proteins (FABPs). Intestinal FABP (I-FABP) is encoded by the FABP2 gene, located on the long arm of chromosome 4. The G to A polymorphism of codon 54 results in the substitution of an alanine residue by a threonine (Thr-54 I-FABP). This variant exhibits a 2-fold greater affinity for long-chain fatty acids when compared to the wild type I-FABP. The mutant allele seems to be associated with insulin resistance and enhanced fat oxidation in Pima Indians, a group recognised to have a high prevalence of type 2 diabetes. Using human jejunal organ culture, we have investigated the relationship between the polymorphism of I-FABP and the intracellular lipid transport in the intestine. We have also sought to determine how the variant allele influences lipid esterification, de novo lipid synthesis, apolipoproteins A-1 and B biogenesis and secretion lipoproteins secretion. Of 32 samples studied, 22 revealed to be wild type homozygous (Ala-54/Ala-54) and 10 heterozygotes (Thr-54/Ala-54). The Thr-encoding allele was associated with increased secretion of newly esterified triglycerides and de novo apo-lipoprotein B synthesis and, elevated chylomicron output. Alterations were observed neither in very low density and high density lipoprotein production nor in apolipoprotein A-1 and microsomal triglyceride transfer protein activity or mass. In the frame of a health and social survey, we have recently examined the relationship between Ala54Thr and, the physical and biochemical characteristics associated with insulin resistance (IRS) in French-Canadian youth. A strong correlation was observed between the Thr polymorphism and total cholesterol and LDL-cholesterol in subjects with IRS, explained by triglyceridemia, without linkage to any of the traits related to IRS. Although this study does not provide evidence on the predisposition to IRS related to this polymorphism, our data suggest that it is related to lipid abnormalities and may therefore play an important role in the development of cardiovascular diseases.
FABP2 Gene Polymorphism and Insulin Resistance
FORUM: EDUCATION FOR PHARMACOGENOMICS, NEEDS FOR CLINICIANS HEALTH SPECIALISTS AND PATIENTS
Frueh F. The goal of the Pharmacogenomics Education online forum is to exchange information, post questions and suggestions about education in this rapidly evolving field. Pharmacogenetics research started decades ago. Evolving into pharmacogenomics using novel technologies, asking new and bigger questions, and the invaluable resource of full genome sequence information on hand, and while gathering huge amounts of data on the scope of human genome variation, we still have not seen a broad dissemination of pharmacogenetics applications in everyday's medicine. Moreover, hopes for development of true personalized medicine within the present and the next decade now seem to be farther away, compared with many hopes just few year ago.
• Why education has been identified as one of the major bottlenecks? How can we solve it? Where and how is pharmacogenetics/-genomics been taught? • How can we effectively move pharmacogenomics from the lab to the bedside? • Where can we find educational material (online or in print)? • Where do we find schools and universities with curricula that include pharmacogenomics? • What should be done to encourage more medical and graduate schools to incorporate the teaching of pharmacogenomics to their curricula? • How should we ensure, as educators, that pharmaco genomics-based diagnostic and treatment tools will only be used according to strict medical ethics?
These and hopefully many other questions will be discussed and answered. It is the goal of this forum to gather a critical mass of information to present and publish the results towards the end of 2004. We would like to encourage you to participate and contribute to the success of this forum and thank you in advance for your time and effort to make this a useful resource for both educators and students.
SESSION: CANCER PREDISPOSITION GENES BIOMARKERS AND POLYMORPHISMS
Molecular Analysis of Cancer in the Post-genome Era
Hanash S.M.* Henry Sewall Endowed Professor, Department of Pediatrics, The University of Michigan Medical Center, USA Much of the spectacular progress in cancer research in the past couple of decades has resulted from the discovery and elucidation of the role of particular genes in tumor development. However it has become increasingly clear that cancer is a complex biological system affected by numerous factors and pathways that dampen or enhance the effects of single genes. Developments in the post-genome era have made it possible to investigate cancer on a global scale and at multiple molecular levels including the genome, transcriptome and the proteome. In approaching cancer as a complex biological system, there is substantial merit in collecting and integrating data obtained at such multiple levels, as no single global analysis platform is fully informative. Deriving knowledge from integrated data is relevant to our understanding of the contributions of specific genome alterations, of the interplay between malignant or pre-malignant cells and the microenvironment in which they reside and of the contributions of host factors and environmental exposures, to tumor development and progression. This knowledge will likely yield more effective strategies for early cancer detection and therapy.
Identification and Tracing of Low-level Mutations in Tumors and their Potential Influence on Drug Resistance
Makrigiorgos M.* Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Detecting the presence and diversity of low-level mutations in human tumors undergoing genomic instability is
Abstracts: Santorini 2004, From human genetic variations to prediction of risks and responses to the environment A33 desirable due to their potential prognostic value and their putative influence on the ability of tumors to resist drug treatment and/or metastasize. However, direct measurement of these genetic alterations in surgical samples has been elusive, as technical hurdles make mutation discovery impractical at low mutation frequency levels (MF<10 -2 ). Here we describe inverse PCR-based amplified restriction Fragment Length Polymorphism (iFLP), a new technology that combines verse PCR, RFLP, and dHPLC to allow scanning of the genome at several thousand positions per experiment for low-level point mutations. Application of iFLP to the screening of sporadic colon cancer surgical specimens demonstrated widespread, low-level mutations in 7 out of 10 samples, at mutation frequency 10 -2 -10 -4 , but not in their normal tissue counterparts, and predicted the presence of millions of diverse, low incidence mutations in certain tumors. dHPLCbased detection of microsatellite instability (MSI) demonstrated the absence of MSI from samples that were positive for low-level mutations. iFLP allows the high throughput discovery and tracing of mutational signatures in human cells, pre-cancerous lesions and primary or metastatic tumors, and the assessment of the number and heterogeneity of mutations in surgical samples. Further envisioned uses of iFLP include evaluating tissues for carcinogenic exposures that generate random, low level mutations and identifying genetic variations (SNPs) in pooled DNA from animals or plants.
Xenobiotic Metabolizing Enzyme Polymorphisms and Cancer Risk
Taioli E.*, Pedotti P., Paracchini V., Raimondi S., Garte S.
Ospedale Policlinico IRCCS Via F. Milano, Genetics Research Institute Strada della Carità, Milano, Italy Polymorphisms in metabolic genes (MGP) have been associated with cancer of various sites. However, the size of individual studies is often too small for allowing conclusions on such associations. A pooled analysis (GSEC study) was started in 1997 (1) , with the aims of studying the role of MGP in cancer risk, gene-environment and gene-gene interaction, using a large data set. The GSEC study includes individual data on over 54,000 subjects, half cases and half controls. Data on rare subgroups are presented, such as bronco alveolar carcinoma, mesothelioma, cancer at young ages, tobacco related cancers in non-smokers. The data set has allowed for the analysis of the association between lung cancer and multiple gene polymorphisms on the pathway of PAH metabolism. The data set has also been used to address methodological issues (2), such as the presence of publication bias, the importance of estimating the appropriate allele frequency in healthy subjects. While large studies involving MGP and cancer as an endpoint are ongoing, pooled analysis seems to be a useful tool for molecular epidemiologists. 
CYP2A6 Polymorphism and Tobacco Related Cancer
Kamataki T.* Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan First, we found three subjects who showed a slow metabolic phenotype in the pharmacokinetics of SM12502. Analyzing the genes for CYP2A6 of the three subjects, we found that the three subjects possessed the whole CYP2A6 gene deletion. Using genetically engineered Salmonella YG7108 cells, we found that CYP2A6 was involved in the metabolic activation of N-nitrosamines such as a tobacco-specific nitrosamine, NNK, which has been known to cause lung tumor in rodents.
Thus, to examine a hypothesis that individuals possessing the CYP2A6*4C have the reduced risk of cancers due to the lack of the metabolic activation of certain carcinogens in tobacco smoke, a case-control study was performed. The results clearly indicated the existence of a significant association between the CYP2A6 genotype and a lung cancer risk in smokers. In contrast, there was no significant relationship between them in non-smokers. It was expected that the inhibition of the enzyme resulted in the reduced cancer risk caused by smoking. The results of experiments using mice which were treated with NNK, a carcinogenic nitrosamine contained in tobacco smoke, together with methoxsalene, a strong inhibitor of CYP2A6, indicated that the inhibition of CYP2A6 completely abolished the occurrence of adenoma.
Cancer Proteomics: From Discovery to Diagnostics
Chan D.W.* Biomarker Discovery Center, Johns Hopkins University, Baltimore, Maryland, USA
Cancer is a proteomic disease. Studies of cancer proteomics not only allow us to better understand the biology of cancer, but also provide us the opportunities to identify protein biomarkers for cancer diagnostics. Since cancer is heterogeneous, it is unlikely that a single biomarker or protein could be used to achieve its full clinical potentials, such as screening, detection, prediction or monitoring of cancer therapy. Maximum clinical usefulness is likely to require a panel of biomarkers.
Current proteomics approaches use technologies such as protein (array) chips of antibodies or surface-enhanced laser desorptionionization (SELDI), multi-dimensional liquid chromatography or two dimensional gel electrophoresis (2D-PAGE). These techniques could be coupled with mass spectrometry such as matrixassisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) or tandem MS. In conjunction with bioinformatics tools, they offer high-throughput protein profiling and greatly facilitate the discovery of new and better biomarkers. Study design, sample collection/processing and data analysis are important issues for a successful proteomics program. Most high-throughput expression data are often characterized by a large number of variables (e.g. the mass peaks) relative to a small sample size (e.g. the number of specimens). An important issue in analyzing such data is to extract as much information as possible from a limited number of samples and to avoid selecting biomarkers whose performances are influenced mostly by non-disease related artifacts in the data. In summary, the combination of proteomics and bioinformatics tools could facilitate the identification of proteins biomarkers of clinical interest. Examples of the biomarker discovery program for ovarian, prostate, breast and pancreatic cancers will be discussed.
Messenger mRNAs and Leukemias: Diagnosis, Follow up and Therapy Monitoring
Salvatore F.* CEINGE -Biotecnologie Avanzate and Dipartimento di Biochimica e Biotecnologie Mediche, Università degli Studi di Napoli "Federico II", Italy
Chronic myeloid leukemia (CML) is a neoplastic disease paradigmatic for "bench to bedside" translation research. In this leukemia, a unique genetic lesion, the Philadelphia chromosome (Ph), that give rise to a oncogenic fusion protein, leads to the disruption of multiple signal transduction pathways in a stem cell, and impairs the balance between the proliferative and differentiation capacity of hemopoietic cells. The Ph is the result of a reciprocal translocation between chromosomes 9 and 22 and leads to the fusion between the BCR and ABL genes. The BCR/ABL protein is leukemogenic because their ABL-derived tyrosine kinases are constitutively activated, and, unlike the normal ABL protein which is tightly regulated, it phosphorylates a large number of intracellular substrates.
In recent years the analysis of specific quantitative mRNAs has allowed to understand directly the molecular basis of oncogene formation and to approach the diagnosis and the follow-up of several leukemic disorders. This approach has permitted to discover a new form of chronic myeloid disease, the neutrophilic chronic myeloid leukemia, with well characterized clinical signs, much milder than the classical form. Furthermore, the possibility to achieve a much earlier knowledge of the efficacy of the response to interferon therapy by an in vitro assay has been achieved. However, the molecular mechanisms of the variable sensitivity of the Ph cells to imatinib and interferon have not been fully elucidated, yet. Our data indicate that the action of these two drugs is associated to variations in the expression of the BCR/ABL gene. Indeed, interferon down-regulates the expression of the BCR/ABL gene in CML cells, and acts synergistically with imatinib to reduce the expression of SHP-1 and P13K genes and the extent of reduction correlates with the apoptotic rate of PL positive cells. Finally, we investigated, in a patient affected by acute lymphoblastic leukemia (ALL), the structure of a novel MLL/AE4 fusion gene. This gene derives from the fusion between two genes both encoding transcription factors. We found that the derived fusion gene lacks either the MLL-and AF4-derived exons which encode transactivating domains, but retains the DNA binding-encoding domains. Consequently, the resulting oncogenic fusion protein is able to bind DNA at specific sites, but lacks the ability to activate transcription at those sites. Therefore, loss-of-function is, very likely, one mechanism involved in leukemic transcription in this sub-set patients.
The work carried out in the Author's Laboratory has been supported by grants from AIRC, MIUR and Regione Campania (Italy).
SESSION: ANTI-CANCER DRUGS AND PHARMACO-GENOMICS
Implications of Acquired Mutations on Therapeutic Response and Drug Resistance
Lilleberg S.L.* Translational and Clinical Research Services, Transgenomic Inc., Omaha, NE, USA Strategies for cancer treatment are evolving at dramatically increasing rates due in part to the the development of target therapeutics. However, there is great heterogeneity in patient responses that often require empirical approaches to define the appropriate treatment for individual patients. The basis of this heterogeneity has two genetic contributions, the inherited (host) genome and the acquired (cancer) genome. The identification of host germ-line mutations in key genes such as those encoding drug metabolizing enzymes, transporters, and drug targets have aided in elucidating the inherited nature of patient differences in drug response, including toxicity, sensitivity, and availability. Pharmacogenetics associated with variability in response to cancer treatment has been eloquently reviewed (1) . This presentation will focus on oncogenetics, and the recent body of work that describes acquired or somatic mutations in the cancer genome that have implications on current cancer therapeutic approaches, including drug resistance. For example, some emerging cancer therapies are directed against receptor tyrosine kinases (RTKs) that are activated in certain tumor types (2) . Abnormalities in some RTKs have been correlated with cancer development and progression, poor responses to traditional chemotherapeutic agents, and poor survival rates (3) . Targeted inhibitors of RTKs have been recently approved for some cancer treatments, while others are in advanced stages of clinical trials. Acquired mutations have been identified in genes encoding a number of these drug targets, related family members, and downstream effectors that are associated with differential therapeutic response rates and drug resistance. The identification of mutations prior to, or during early treatment stages would provide tremendous advantages to the oncologist and patient. Highly sensitive in-depth approaches to somatic mutation scanning will be described in this context.
In all cases, the 2-D maps, developed with a fluorescent stain, Sypro ruby, compatible with subsequent mass spectrometry analysis, revealed >700 polypeptide chains, in the pH 3-10 interval. After comparing the master map in the four different conditions, and by summing up all the four treatments, more than 100 different proteic spots were found to be up-and down-regulated, comprising a few species which were turned on/off after the different drug treatments. The modulated proteins, which might be responsible for resistance to cisplatin, could be classified under various categories, such as molecular chaperones (e.g., heat shock proteins HSP60, HPS71, HPS90), Ca 2+ -binding proteins (e.g., calmodulin, calumenin), proteins involved in drug detoxification (especially in red-ox reactions, such as peroxiredoxins 2 and 6), anti-apoptotic proteins (particularly Bcl-2 and 14-3-3, the latter switched on in cisplatin-treated cells) and ion channels (such as VDAC-1, voltage-dependent anion selective channel). Of particular interest might be those proteins whose synthesis is modulated in two or more treatments, such as calmodulin, VDAC-1, microtubule-associated protein RP/EB, heat shock cognate 71 kDa protein, 14-3-3 protein, stathmin and peroxyredoxin isoforms. Genetic polymorphism in drug metabolizing enzymes contributes to susceptibility to a number of diseases. Identification of certain allelic variants of drug metabolizing enzymes as genetic susceptibility markers can provide important tools in early diagnosis and prevention. Recently, a steady increase in a frequency of female hormonedependent cancer through the world has been observed. Among causes of such an increase are endocrine disorders, environmental factors and genetic predisposition. Certain allelic variants of cytochrome P450: CYP1A1, CYP1A2, CYP19 (Aromatase) and II-phase enzyme SULT1A1 (Sulfotransferase) genes are shown to be associated with a high risk of hormone-dependent cancer. We estimated a frequency of these allelic variants in the female population of the Novosibirsk region and their association with the elevated risk of ovarian and endometrial cancer. We created a DNA bank of cancer patients and healthy women. We studied single nucleotide polymorphisms (SNP) for CYP1A1: T264→C; for CYP1A2: C→A at 734 position from transcription start; for CYP19: C→T in non-translated region of 10th exon; for SULT1A1: G638→A. For genotyping of the studied population PCR RFLP-based assay was used. Exfoliated buccal cell samples were collected from 120 healthy controls and 150 cancer patients as a source of genomic DNA for genotyping assays. Diagnostics and clinical protocol were performed by medical doctors from Regional Clinical Oncological Hospital of Novosibirsk. The frequencies of CYP1A1 and CYP1A2 mutant alleles were higher in hormone-dependent cancer patients. No association with CYP19 and SULT1A1 polymorphisms was revealed. We showed positive correlation of mutant allelic variants of drug metabolizing enzymes with hormonedependent cancers in women. Thus, the studied genes are appropriate candidates for study of genetic factors of susceptibility to endocrine disorder and environmentally determined diseases.
Case-control Study of Polymorphism of Drug Metabolizing Enzymes and Human Hormone-dependent Cancer
Supported by a Grant "Universities of Russia" (No UR 11.01.009). Effectiveness of 5-Fluorouracil based hemotherapy (5FU) is variable according to the expression of thymidylate synthase (TS) which is affected by a double (2R) or a triple tandem repeat in the promoter region or by a deletion of 6 bp in the 3'UTR. Lethal or severe 5-FU toxicity is associated to the presence of a rare (0.1%) polymorphism (DPYD*2A) in the splicing region of intron 14. In addition, the presence or absence of functional p53 in tumor may be an important determinant of the chemosensitivity of a tumor. In this context, we carried out a retrospective study of 24 patients ORL cancer treated with 5-FU. After extraction of genomic DNA, DPYP*2A was analysed on a Lightcycler ® automate, TS polymorphisms were analysed by RFLP analysis. P53 status was determined by SSCP and sequencing, immunohistochemical and antibodies anti-p53 detection. Distribution of 5'TS genotype was 18% 2R/2R (n=4), 36% 2R/3R (n=8) and 36% 3R/3R (n=8). Distribution of 3'TS genotype was 45% 6bp/0bp (n=10), 14% 6bp/6bp (n=3) and 32% 0bp/0bp (n=7). The median survival time was 26 months in patients homozygous or heterozygous for the 2R mutation versus 14 months in patients homozygous for the 3R mutation. 23% of patients carried a mutation of p53, p 53 overexpression was detected in the tumors of 17 patients (81%), anti-bodies anti-p53 were detected in the serum of 5 patients (33%). P53 overexpression and TS status appear to be associated with poor response. In the patients who developped poor response to 5-FU, analysis of the TS status showed that 55% of the patients (n=12) were heterozygous or homozygous for the 3R mutation for, 50 % (n=11) for the 6bp deletion. Overexpression was detected in the tumor of 13 patients (62%). Concerning hematological, digestive or mucositis/ stomatitis toxicity related to DPYD*2A, all patients displayed a homozygous wild genotype whereas the TS status seemed to be relevant. Our study is a first step toward the goal of tailored cancer chemotherapy. These findings will be next discussed. CYP3A4 is responsible for the metabolization of numerous xenobiotics and endobiotics, including environmental carcinogens. One of its known substrates is benzopyrene, a tobacco smoke constituent, and a sub-product of vegetal oils cooking, that interacts with DNA forming DNA-adducts and inhibits BRCA1 gene expression (1, 2) . Although epidemiological studies on the potential role of tobacco smoke on breast Carcinogenesis are conflicting, the described expression of CYP3A4 and its transcriptional nuclear regulator PXR in breast tissue leads us to hypothesize that polymorphism in these genes may be involved in the variable risk for breast cancer (3, 4, 5) . In this study we investigated the presence of variants with known altered CYP3A4 activity or PXR induction activity, namely CYP3A4*12, CYP3A4*17, CYP3A4*18A, PXR D163G and PXR V140M (6, 7, 8, 9) . Novel PCR-RFLP methods were developed for the detection of these SNPs, in a case-control study in Caucasian subjects. None of the polymorphisms were detected in the studied populations, suggesting that these CYP3A4 and PXR SNPs correspond to rare variants, and appear not to be directly involved with the breast cancer etiology. resistance has not been clarified yet, though glutathione (GSH) is likely to have a role for the resistance to occur. N-acetylcysteine (NAC) is a pro-glutathione drug. DLButhionine (S,R)-sulfoximine (BSO) inhibits GSH synthesis. The aim of our study was to investigate the effect of NAC and BSO on MRP1-mediated doxorubicin resistance in Human Embryonic Kidney (HEK293) and its MRP1 transfected 293MRP cells. Human Embryonic Kidney (HEK293) cells were transfected with a plasmid encoding whole MRP1 gene. Both cells were incubated with doxorubicin in the presence or absence of NAC and/or BSO. The viability of both cells were determined under different incubation conditions. GSH, GST and GPx levels were measured in the cell extracts obtained from both cells incubated with different drugs. NAC increased the resistance of both cells against doxorubicin. Buthionine sulfoximine (BSO) decreased NAC-enhanced MRP1-mediated doxorubicin resistance, indicating that induction of MRP1-mediated doxorubicin resistance depends on GSH synthesis. Doxorubicin decreased cellular GSH concentration and increased glutathione peroxidase (GPx) activity. Glutathione S-Transferase (GST) activity was decreased by NAC. Our results demonstrate that NAC enhances MRP1-mediated doxorubicin resistance and this effect depends on GSH synthesis. BSO seems a promising chemotherapy improving agent in MRP1 overexpressing tumor cells. The importance of GST and GPx enzymes and/or their possible contribution to doxorubicin resistance in MRP1 overexpressing cells remains to be determined.
Genotyping of Thymidylate
CYP3A4 and PXR Gene Polymorphisms in Breast Cancer Patients
SESSION: GENE REGULATION, DRUG TAGETS AND BIO-MARKERS
F Fl lo ow w C Cy yt to om me et tr ri ic c A An na al ly ys si is s o of f S Si ig gn na al l T Tr ra an ns sd du uc ct ti io on n P Pa at th hw wa ay ys s Shankey T.V.* Advanced Technology Center, Beckman Coulter, Inc., Miami, USA Signal transduction pathways represent the major communications networks that transmit signals from multiple cell surface receptors to the nucleus, generally resulting in activation of specific target genes. These pathways serve an important function in integrating signals from multiple independent inputs, with the overall output serving to signal cell death, or survival, proliferation, or cell differentiation (reviewed in 1). We have used flow cytometry to analyze signal transduction pathways, including the MAP kinase pathway. These studies have included the analysis of molecularly targeted inhibitors designed to interrupt specific signal transduction molecules. The unique aspects of this technology include the ability to monitor specific pathways in distinct populations in heterogeneous cell mixtures. Finally, data will be presented to demonstrate the utility of flow cytometry to monitor in vitro or in vivo responses of individual patients with Chronic Myelogenous Leukemia (CML) to Gleevec (STI571), the drug now commonly used to inhibit the Bcr/Abl receptor tyrosine kinase. These studies have involved model tissue culture systems (2) and more recently monitoring CML patient responses to Gleevec by using flow cytometry to measure the phosphorylation status of STAT5 and downstream proteins in conjunction with cell surface markers routinely used to characterize haematological malignancies.
Identification of Diagnostic Markers for Colorectal Cancer by Expression Profiling of Human Tumors
Maimonis P.* M Me et th ho od ds s: : CD34/AC133 were isolated from human cord blood using magnetic microbits (Milteny Biotech). Primary cultures of human endothelial cells (HUVEC) were isolated from human umbilical vein using collagenase digestion method. Cells were grown in EBM medium with supplement and antibiotics. Influence of PPARs activators (FFA, lysophosphatidilcholine (oxPAPC, SPP-1)) or β-carotene on the gene expression after 24 hour incubation was compared using real-time PCR (Opticon) or by oligonucleotide chips (Affymetrix). To determine the effect of factors on cell proliferation the rate of DNA synthesis was estimated by measuring BrdU incorporation. Influence of above compounds on angiogenesis was investigated by the tube formation assay in the 3D in vitro Matrigel model. Chemotaxis was performed using BD Falcon Fluoro Bloc System (Becton Dickinson). The changes in certain protein synthesis were proved by flowcytometry. R Re es su ul lt ts s: : On the contrary to VEGF, bFGF or leptin, the PPAR-γ activators and β-carotene in non-toxic concentrations did not significantly influence the proliferation and the tube formation in the tubulogenesis model in vitro. In spite of not significant influence of modified lipoproteins (ox LDL, oxPAPC) on HUVEC or EPC migration, the VEGF or SDF-induced chemotaxis was significantly modified. β-carotene alone stimulated chemotaxis of the EPC. Microarray and real-time PCR analysis indicated that beta -carotene activated the gene expression connected with cell differentiation, cell cycle, adhesion, cell-cell signalling chemotaxis, apoptosis as well as with induction of cyt P450 pathway of xenobiotic catabolism. The down-regulation of Egr-1 transcription factor may be the common link between the observed pathways. Ciphergen Biosystems, Inc., Fremont, CA, USA A collaborative study was undertaken between Ciphergen and McGill University in order to identify diagnostic markers for Chagas' Disease, or chronic Trypanosoma cruzi (T. cruzi) infection. Chagas' Disease is endemic to Central and South America, is notoriously difficult to diagnose, and can remain asymptomatic for decades as the parasites slowly infest and destroy the patients' heart muscle through fibrosis. Discovery of diagnostic markers is particularly important in the view of the Red Cross and Health Canada due to the 5-7% seropositive rate of immigrant blood donors in North America. Existing diagnostics are primarily ELISAs that rely on detection of antitrypanosomal antibodies, and these have a high false-positive rate. PCR-based tests have high false negatives due to the life-cycle of the parasite, and there is no current FDA-approved diagnostic available. Collaborators from McGill obtained 39 asymptomatic Chagas serum samples and 34 age-matched uninfected controls from Dr. Alberto Ache at the Venezuelan Ministry of Health. The serum samples were fractionated and profiled on WCX and IMAC-Cu arrays, and data was analyzed using a Ciphergen software package that included Biomarker Patterns Software. A panel of markers were discovered and identified a that are capable of diagnosing asymptomatic Chagas' Disease with sensitivity and specificity in the midninetieth percentiles. Most of these markers are specific fragments of host-response proteins, although one notable protein at 110 kD was a previously undescribed protein derived from the T. cruzi parasite. Proteins were ID'd by peptide mapping on PBS-IIc and confirmed by tandem MS using the ProteinChip Interface on the QStar. Currently multiple disease controls are being run at McGill, including African sleeping sickness, Babesiosis, Leishmaniasis, syphilis, Schistosoma, West Nile, and myocarditis samples. Thus far the pattern of markers identified has remained unique for Chagas' disease, and is not shared in whole or in part by the other disease samples. It is hoped that this publication will stimulate the interest of the diagnostic and infectious disease communities.
Identification, Functional and Structural Characterization of Novel Bacterial RNAs; Putative Targets to Develop Antibiotics
Antal M., Pichon C., Bordeau V., Felden B.* Université de Rennes I, Biochimie Pharmaceutique, Faculté de Pharmacie, Rennes, France Small bacterial regulatory ribonucleic acids (RNAs) are far more abundant than previously anticipated, and their biological roles remain largely unknown. Some are involved in bacterial pathogenicity and virulence, that might be considered as promising targets to develop new antibiotics. A program that helps identifying novel bacterial RNAs was designed 1 and tested on both gram positive and negative bacterial species, some involved in infectious diseases. All the recently characterized RNAs by other groups, mostly in E. coli, were identified (reviewed in 2), plus several new ones. On all these RNAs, transcriptomic analyses combined to Northern blots, 5' and 3'-ends mapping, gene disruption and over-expression were performed, combined to structural analysis. Also, a methodology was developed to detect the molecular targets of these RNAs. Some of these novel results will be presented and discussed. India shows the highest number of tuberculosis (TB) cases in the world with an incidence rate of 200 per lakh and almost twice that of China. Lungs serve as portal for the entry of Mycobacterium tuberculosis, the most important etiologic agent of TB. Lung response to this threat is coordinated by alveolar macrophages. Components of alveolar surfactant and especially the hydrophilic surfactant proteins namely lung surfactant protein A (SP-A) and surfactant protein D (SP-D) have received increasing attention as innate immune molecules activating alveolar acrophages. SP-D is an important pulmonary opsonin that recognizes a wide array of microorganisms through the carbohydrate recognition domain (CRD). A series of studies from our group has confirmed that SP-D is involved in host defense against allergic and invasive forms of aspergillosis (1) (2) (3) (4) . Recently, C terminal region (comprising of CRD) of SP-D is shown to enhance membrane permeability of bacteria (5). SP-D has also been shown to bind to lipoarabinnomannan moiety on surface of Mycobacterium tuberculosis bacilli through CRD and this interaction results in reduced uptake of bacteria by alveolar macrophages (6, 7) . In view of these studies implicating SP-D in host defense against tuberculosis (TB), and association of polymorphisms in related proteins SP-A2 (8) and MBL (9) with tuberculosis patients of Indian origin, various regions of the SP-D gene were screened in tuberculosis patients and controls of Indian origin. SP-D gene from Indian subjects differed from the reported SP-D sequence from Caucasian subject at 15 nucleotide positions. Comparative analysis of the allele frequencies of six SNPs of TB patients with the healthy control subjects showed that SNP G459A (p= 0.01; OR 3.04) (TB patients n=25, Controls n=13) (redundant polymorphism in exon 7 encoding CRD) and T3130G (p= 0.00; OR 13.75) (intron 6) (TB patients n=12, Controls n=17) were significantly associated with TB in Indian population. The results indicated that these SNPs in the carbohydrate recognition domain and intron 6 of SP-D may be one of the contributing factors to the genetic predisposition to pulmonary tuberculosis in Indian subjects. Aβ peptide is the major proteinateous component of the amyloid plaques found in the brains of Alzheimer's disease (AD) patients and is regarded by many the culprit of the disorder. It is well documented that brain lipids are intricately involved in Aβ-related pathogenic pathways. An important modulator of lipid homeostasis is the pluripotent peptide leptin. Here we demonstrate leptin's ability to modify Aβ levels in vitro and in vivo. Leptin, similarly to methyl β-cyclodextrin, reduces β-secretase activity in neuronal cells, possibly by altering the lipid composition of membrane lipid rafts. This phenotype contrasts treatments with cholesterol and etomoxir, an inhibitor of carnitine-palmitoyl transferase-1. Conversely, inhibitors of acetyl CoA carboxylase and fatty acid synthase mimicked leptin's action. Additionally, leptin was able to reduce apoE-dependent Aβ uptake in vitro. Thus leptin can modulate indirectly bi-directional Aβ kinesis, reducing its levels extracellularly. Most strikingly, chronic administration of leptin to AD-transgenic animals reduced the brain Aβ load, underlying its therapeutic potential. The response to drugs (efficacy or toxicity) is extremely variable. It depends largely on the metabolism. This metabolism is also extremely variable and is under the control of environmental, patho-physiological and genetic factors, the latest being the topic of this lecture. The metabolism can be divided in three phases (I, II and III). Among phase I, cytochromes P450 (CYP) are the most important enzyme superfamily. Genetic variations in CYP are now known since the discovery of CYP2D6 genetic polymorphisms more than 25 years ago. Most of the CYP implicated in drug metabolism present gene-tic polymorphisms with functional consequences, the inactive allele being often present with a high frequency (more than 1%). It is also interesting to observe that in some cases gene duplication can be observed (CYP2D6, 2A6), leading to an over-expression of the corresponding CYP. Thus, in a population several type of metabolizers may be observed: slow, intermediate, rapid and ultra rapid showing that genetic factors may influence drastically the metabolism and thus the pharmacokinetics and pharmacodynamics of drugs. It is quite interesting to observe that the frequency of the different categories varies among populations. Now, easy methods are available to genotype and/or phenotype in order to identifiy individuals with such genetic variations. The lecture will show that in several cases these polymorphisms have clinical implications and that the determination of the metabolic capacity is in some instances a useful predictor of the response to a drug. This approach is particularly useful in the cases of drugs with a low therapeutic index or for which the effect cannot be assessed rapidly e.g. anti-cancer, psychotropic or immunosuppressive drugs. However, before the general use of such approach, prospective clinical studies are needed to definitely validate its predictive efficacy. The cytochrome P450 (CYP) 2D6 enzyme is involved in metabolism of about 25% of all drugs. Genetic polymorphisms in CYP2D6 can either lead to complete deficiency of the enzyme or to high activity causing ultrarapid metabolism which is caused by duplicated active genes. In Caucasians, about 7-10% are so-called poor metabolizers of CYP2D6 substrates and as a consequence are at an increased risk of adverse drug reactions. In contrast, about 3% of Caucasian individuals are carriers of the CYP2D6 gene duplication and have a risk for therapeutic failure due to high metabolic activity and low plasma concentrations of drugs that are CYP2D6 substrates. Clinical data on CYP2D6 polymorphisms in antidepressants reveal large differences in pharmacokinetic parameters such as plasma concentrations, drug clearances and elimination half-lives. Up to tenfold differences in oral clearance of antidepressants between poor and ultrafast metabolizers have been described and can be translated into clinically relevant dose adjustments. For antiemetics, sufficient efficacy has been observed in the slow metabolizer groups whereas the extensive and ultrafast metabolizers were at risk for therapeutic failure. In metoprolol therapy, the antihypertensive effects and lowering of the heart rate depended on CYP2D6 genotype which corresponded well to the genetically caused differences in pharmacokinetics. CYP2D6 also plays a role in brain metabolism of endogenous substrates from the serotonergic and dopaminergic pathways such as methoxytryptamine and methoxyindolethylamine playing a role in the serotoninergic system. Genotyping for CYP2D6 polymorphisms has become widely available during the past years and pharmacogenetic diagnostics is discussed as a clinical tool to improve and individualize drug treatment. However, the clinical implication of genotyping is not yet evident. Prospective studies on the benefit of genetics-based therapeutic modifications such as genotype-based dose adjustments have to be performed as well as patient studies on the cost-benefit analysis of genetic diagnostics.
Obesity-related Leptin Regulates Alzheimer's Ab
SESSION: DRUG OR ENDOBIOTE METABOLISM AND PHARMACOGENETICS
Main CYP Polymorphisms Implicated in Drug Metabolism
Polymorphisms of Human Aldehyde Dehydrogenases: Impact on Metabolism and Disease
Vasiliou V.*, Pappa A., Estey T., Lassen N.
Molecular Toxicology & Environmental Health Sciences
Program, Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Denver, USA Aldehydes are highly reactive molecules that are generated from chemically diverse endogenous and exogenous precursors. Aldehydemediated effects vary from homeostatic and therapeutic to cytotoxic, and genotoxic. One of the most important pathways for aldehyde metabolism is their NAD(P)-dependent oxidation to carboxylic acids by aldehyde dehydrogenases (ALDHs). Seventeen functional ALDH genes have been identified in the human genome. Disease phenotypes or pathophysiologies are associated with polymorphisms in several human ALDHs, supporting the importance of ALDHs as detoxifying enzymes. Polymorphism in ALDH2 is associated with decreased acetaldehyde metabolism and risk of alcoholism, increased risk of ethanol-induced cancers and the late-onset of Alzheimer's disease. Mutations in ALDH3A2 causing loss of enzymatic activity represent the molecular basis of Sjögren-Larsson syndrome. Mutations in ALDH4A1 are associated with type II hyperprolinemia, and deficiency in ALDH5A1 causes 4-hydroxybutyric aciduria.
Lack of ALDH6A1 appears to be associated with developmental delay, whereas the implication of ALDH3 family genes as predisposing factors to schizophrenia has been recently suggested. In addition to detoxification, a number of ALDH-mediated oxidations are known to form products with significant biologic, therapeutic and/or toxic activities. These include the retinoic acid, an essential element for vertebrate development, γ-aminobutyric acid, an important neurotransmitter, and trichloroacetic acid, a potent toxicant. (Supported by R01AA11885 & R01EY11490) .
ABC Transporter Polymorphisms, Xenobiotic, and Endogenous Substrates Responses
Schmitz G.* Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany
The importance of ATP-binding cassette transporters in human xenobiotic and drug metabolism has been recognized since many years. ABC Transporters including MDR1, several MRPs and members of the ABCG subfamily are both constituents of beneficial phase 3 detoxification mechanisms and are concomitantly responsible for detrimental effects by causing clinical multidrug resistance. Furthermore, ABCA1, ABCA7, ABCG1, ABCG5, and ABCG8 are functional components of cellular phospholipid and sterol homeostasis. Genetic polymorphisms in these genes are therefore interesting targets for pharmacogenetic analyses in humans related to xenobiotic and drug metabolism as well as pathophysiology of lipid metabolism. Using large scale gene expression profiling of biopsy samples from patients with Inflammatory Bowel Disease based on biomedical pathway analysis of DNA microarray results, we have identified a PXR-mediated dysregulation of intestinal detoxification pathways including phase 1 and phase 2 enzymes and ABC transporters. Analysis of genetic variations in the regulatory regions of these genes may provide novel susceptibility markers for Ulcerative Colitis and Crohn´s disease and may be useful for optimized IBD diagnosis and therapy. Furthermore, we describe the identification of novel sequence variations within ABCA1 and the promoter region and provide functional testing of a mutation in the regulatory region. To facilitate further research in ABCA1 sequence variations and expand our understanding of their effects, we are introducing a webpage archive (http://www.abca1-mutants.all.at) containing all sequence variations reported in ABCA1 so far. This webpage provides a more recent and detailed summary of sequence variations and mutations in ABCA1 than existing databases and should also be of interest for molecular diagnosis of ABCA1 related HDL deficiency.
Integration of Preclinical and Clinical Pharmacogenomics in Drug Development
Vonderscher J.* Novartis Institutes for BioMedical Research, Inc, Cambridge, USA Pharmacogenomics and its related technologies is still an emerging field that bears a lot of expectations. It is viewed as a key element which will allow new concepts as Individualized/Personalized Medicine to translate into facts. As all new areas it has raised expectations which were boosted by fundamental scientific breakthrough like the sequencing of the genome but it has also already shown some disappointments. Where the expectations just too high or where the avenues used up to now dead end roads? Maybe the various potentially helpful technologies were just not (enough?) used in an integrative manner. We firmly believe that the full potential of pharmacogenomics to design new therapies will only be achieved through an integration of the different approaches like gene expression profiling, proteomics & metabonomics, pharmacogenetics, imaging techniques, etc. The integrated technologies would need to be incorporated from early discovery through pre-clinical, and ultimately to clinical development & Marketing. This integrated approach will hopefully allow the identification of molecular pathways & drug specific efficacy/safety markers, and the selection of valuable targets. Ultimately, the most appealing goal of providing the right drug for the right indication to the right patient can be achieved with the integrated technologies.
Population Genetics and High-throuput Expression Analysis: A Powerful Hybrid Approach to the Genetics of Drug Response
Hakonarson H.*, Hakonarson E.F.
Decode Genetics Inc, Reykjavik, Iceland deCODE has compiled the world's most comprehensive collection of population data on geneaology, genotypes and phenotypes. This unique combination of resources provides a uniquely effective system for identifying key genes linked to diseases as well as other phenotypes, such as drug response. In its growing pharmacogenomics program, deCODE combines this population linkage approach with high-throughput expression profiling to develop efficient and highly accurate measures of responsiveness to any drug of interest. deCODE has, for example, developed an assay for corticosteroid responsiveness in asthma patients, which by measuring the expression pattern of six genes can identify responders with greater than 90% accuracy. On its own and with corporate partners, deCODE is using its technology to develop pharmacogenomic tests. The company believes that such tests are going to be a central part of delivering more personalized medicine, helping to optimize the benefit and safety of drugs. Pharmacogenomics can also aid in the stratification of clinical trials, potentially speeding the approval process while delivering the best drugs to the right patients. Adrenergic receptors are G-protein coupled receptors (GPCRs) that mediate the effects of epinephrine and norepinephrine in the sympathetic nervous system for maintenance of physiological homeostasis and response to disease. Several common naturally occuring polymorphisms in the coding regions of human adrenergic receptor genes have been identified and characterized (1) . Clinical genetic studies have already shown interesting associations of these polymorphisms with clinical phenotypes and response to therapy in certain populations (2) (3) (4) (5) (6) . The functional consequences of these polymorphisms on the biochemical phenotype of the receptor and the receptor signaling has been studied in transfected cells (1) (2) (3) (4) (5) (6) (7) . We have specifically analyzed the signal transduction pathways of alpha2-adrenergic receptor subtypes (α2A, α2B, α2C) (8) as well as the biochemical properties of an insertion/deletion (Glu 301-303) polymorphic α2B-AR in comparison to the wt, in PC12 cells, a sympathetic like neuronal cell line. We found that the major consequence of the polymorphic deletion imposed on the α 2B -AR is that of significantly impaired agonist-promoted phosphorylation, which leads to impaired short-term functional desensitization, but does not affect the internalization or resensitization properties of the receptor. The significance of the altered biochemical properties of polymorphic receptors, acting seperately or in synergy (9) , in the pathophysiology of disease will be discussed.
SESSION: PHARMACOGENOMICS OF NEUROLOGICAL
Pharmacogenomics for Pain Management and Forensic Toxicology
Wong S.W.* Pathology Dept., Medical College of Wisconsin, and Milwaukee County Medical Examiner's Office, Milwaukee, USA Pain management and psychiatric disorders including depression, anxiety, psychosis and others have been effectively treated with analgesic, antipsychotics and antidepressants. These drug groups have been identified as the leading causes of drug deaths by the American Association of Poison Control Centers. Analgesic encompasses a large number of drugs including salicylates, acetaminophen, ibuprofen and COX-II inhibitors, and opioids including codeine, morphine, oxycodone, methadone and others. Methadone is used for both pain management and the treatment of drug addiction. Recently, oxycodone abuse and diversion occurred as a result of Oxycontin TM abuse, followed by an emerging trend of methadone abuse and diversion. The clinical use and abuse of these drugs for the treatment of pain and psychiatric disorders may result in toxicity and in some cases, fatality. The outcomes may be, in part due to pharmacogenomics-drug metabolism difference as a result of genetic variations in drug metabolizing enzyme, drug transporter protein and receptors. The rationale for studying pharmacogenomics is: to personalize/individualize drug therapy for pain management., and to explore the use of pharmacogenomics as an aspect of molecular autopsy in forensic pathology/toxicology. This presentation will focus on the study design and preliminary results from several clinical studies. In the pain management study, selected opioid analgesics were quantitated by LC/MS/MS. Postmortem toxicological analysis of blood and other tissues utilized a variety of techniques including GC, GC/MS and immunoassays. Genotyping was achieved by using several techniques including realtime PCR and Pyrosequencing TM . Preliminary pain management study showed that there is a higher incidence of side effects associated with presence of genetic variations of polymorphic CYP 450 2D6, 2C9, and 2C19. Postmortem studies of methadone, oxycodone and antidepressant deaths showed a lower prevalence of wild type CYP 2D6 alleles. These findings provide some indication of the pharmacogenomics contribution to drug therapy and toxicity.
Pharmacogenetics and Schizophrenia
Ntzani E.E.*, Ioannidis J.P.A.
Department of Hygiene and Epidemiology and
Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece and Department of Medicine, Tufts University School of Medicine, Boston, USA Schizophrenia is a common complex disease that requires chronic treatment with highly variable response rates and outcomes. There is considerable interest in understanding the genetic risk factors that modulate the outcomes of patients under treatment. A systematic evaluation of the lite-rature shows that over 120 studies have been published to-date addressing the effects of various gene polymorphisms on the risk of suffering specific adverse events from pharmacological intervention (tardive dyskinesia, extrapyramidal symptoms, weight gain or agranulocytosis) or having a good or poor response to treatment. The vast majority of these studies have been of limited sample size; none has recruited over 1000 patients with schizophrenia, the sample size that would be required to have reasonable power to detect the existence of an association of modest effect size. The largest studies in the field have failed to show clear-cut associations and some of the early proposed associations have been refuted or not fully validated by subsequent evidence. The majority of the postulated genetic associations however have been tested only in one or two studies and given the limited sample size it is probable that it would be wrong to abandon these hypotheses without testing them in larger populations. Several metaanalyses have been conducted for specific schizophrenia pharmacogenetic associations and although they suggest significant associations overall, their results tend to be susceptible to the effect of excluding the first, hypothesis-generating study and/or they have positive bias diagnostics. Some other important issues in this field include the definition of clinical outcomes, measurement error for various scales, blinding, frequent deviation from Hardy-Weinberg equilibrium in highly selected populations, racial diversity-population stratification, publication bias, standardization of genotyping for polymorphic markers and the difficulty to capture appropriately gene-gene and gene-environment interactions. These issues need to be addressed seriously to enhance the validity of the research findings. Hopefully important associations may become established and fully validated in the near future. The risk of cardiotoxicity and sudden death due to Torsade de Pointes Type arrhythmia during treatment with antipsychotic drugs might be due to unexpected plasma concentration of antipsychotic drugs and/or its metabolites. The polymorphism of the cytochrome P450 enzymes (CYPs) involved in antipsychotic drugs metabolism might explain the reported inter-and intraindividual variability on drug plasma concentration.
CYP2D6 and CYP2C9 and QTc Interval Lengthening During
The present studies were aimed at evaluating the influence of CYP2D6 and CYP2C9, on QTc interval during antipsychotic treatment. Patients during treatment with haloperidol, thioridazine or risperidone antipsychotic monotherapy under steady-state condition were studied. Drug and metabolites plasma concentration, cytochrome phenotypes and genotypes and QTc interval lengthening were studied. The CYP2D6 and CYP2C9 allele frequencies found among patients were similar to those previously described among healthy volunteers. Haloperidol: 11% of patients were identified as having a QTc interval longer than 456 msec, which is considered as the threshold value for the risk of arrhythmia. Thioridazine: QTc interval lengthening was correlated with the plasma concentration (r=0.29, p<0.05), and debrisoquine MR (r=0.31, p<0.01). Risperidone: CYP2D6 active genes were related to QTc interval (p<0.05), and also to the dose-corrected plasma concentration (p<0.05), which is also correlated to debrisoquine MR (r=0.79, p<0.001). The influence of CYP2D6 on QTc interval lengthening during treatment with antipsychotic drugs has been demonstrated. Thus the relevance of pharmacogenetic factors during treatment with antipsychotic drugs might be taken into consideration. In patients with risk factors, cautious dosage and ECG monitoring is suggested due to the increased risk of developing potentially fatal cardiac arrhythmias and sudden death during haloperidol, thioridazine and risperidone treatment. , were shown to be susceptibility genes for schizophrenia. In our laboratory, we selected the more than one hundred candidate genes from previously published works with positive results on various viewpoints, such as immunological, neurodevelopmental, endo-crinological and cell death. More than one hundred Korean schizophrenia patients and normal controls were studied in each association study. Genotype and allele frequencies of several genes showed significantly difference between Korean schizophrenia and normal controls. Also, significant differences were showed in several genes by haplotype or association study. We mapped those possible candidate genes preliminarily in Korean schizophrenia patients. In the future, this map could be used as a powerful tools for study in the molecular pathophysiology of schizophrenia. In the Division of Functional Genome Analysis, we are developing technologies for the identification, description and evaluation of cellular functions and their regulation by producing and processing biological information on a genomic scale. One emphasis in our efforts is work on DNA-, proteinand peptide-microarrays. Many chemical and biophysical issues are being addressed as part of this work in an attempt to understand the underlying procedural aspects, thereby eventually establishing superior analysis procedures. Based on the technical advances, the resulting methods are immediately put to the test in relevant, biologically driven studies on various organisms. Concerning the analysis of human material, systems are being developed toward early diagnosis, prognosis and evaluation of the success of disease treatment with accentuation on cancer. Beside other applications, analyses are performed on the detection and use of disease relevant polymorphisms in the area of molecular epidemiology. Also, comparative studies on epigenetic variations, transcript levels and actual protein expression by means of complex DNA-and antibody microarrays are under way. Early diagnosis from body fluids is being worked at that is based on the binding of serum components to peptide microarrays. Combining this data with clinical information permits the definition of sub-groups within an analyzed cohort and eventually provides a robust means for diagnosis and prognosis as well as the identification of highly relevant targets.
Proteomics and Its Applications in Pharmaceutical Industry
Langen H.* Roche Center for Medical Genomics, F. Hoffmann-La Roche, Basel, Switzerland Information is not only stored in genes but modulated by differently expressed proteins and their modifications. The protein profile present at a given time in a biological system will be different once the shift from the "healthy" to the "diseased" state occurs. Tracing such "Disease-specific proteins" (DSPs) with analytical approaches summarized under "proteomics" is a promising way to arrive at the needed diagnostic tools and will help to understand the molecular mechanisms of disease. Our proteomics approach makes use of subcellular fractionation and the removal of abundant proteins prior to separation techniques like 2D-gel electrophoresis. We separate several hundred proteins in one gel, followed by mass spectrometry for the rapid identification of these proteins. Many steps in the process are completely automated like the robotic gel processing and mass spectrometry. With our high throughput system we can produce several thousand peptide fingerprints per day. Several examples of the application of proteomics in pharmaceutical industry from early target identification to applications in biomarker programs in clinical trials will be shown.
A42 Abstracts: Santorini 2004, From human genetic variations to prediction of risks and responses to the environment
Mapping the Molecular Diversity of Tumor Blood Vessels for the Development of Targeted Therapies and Imaging Agents
Pasqualini R., Arap W.
University of Texas M. D. Anderson Cancer Center, Houston, USA Despite major progress brought about by the Human Genome Project, the molecular diversity of human blood vessels remains largely unexplored. Our research is aimed at targeting diagnostic and therapeutic agents to blood vessels by using probes that can bind to specific vascular addresses. Towards this goal, we developed technologies to identify small peptides that target the endothelium. Different strategies are used to isolate peptides from large libraries displayed in the surface of bacteriophage. Through this platform technology, we have uncovered various tissue-specific and angiogenesis-related vascular addresses. This complex system of ligand-receptor pairs will lead to a better understanding of tumor circulatory microenvironment, changes in blood vessels during tumor progression, and the localization of novel markers in cancer and other diseases with an angiogenesis component. This lecture will review several targeting strategies that may enable the construction of a molecular map outlining vascular diversity in each organ, tissue, or disease.
Integrated Health Care -An Industrial Vision
Naraghi M.* SVP Business Developmen, Siemens AG, Medical Solutions, Erlangen, Germany Siemens Medical Solutions' strategy is focused on developing and delivering health care solutions which increase the quality of care and its efficiency. Our vision of Integrated Health Care is one which (i) Addresses medical needs through all stages in the health continuum: from prevention over diagnosis and therapy to home care/aftermonitoring, (ii) Builds on leveraging the power of molecular technologies, both for in-vivo imaging and in-vitro diagnostics, to unlock their potential for clinical use, (iii) Uses information technologies (IT) to integrate patientrelated medical information across the health continuum and extract, structure and present actionable medical knowledge to the practitioners within the context of clinical decision support systems and (iv) Has a disease-and workflow orientation to enable standard-setting within efficient processes
As an illustrative example, we will discuss how the clinical management of lung cancer cases in the future could like according to our vision. The focus will be on outlining the integration of imaging, molecular methods and IT to shape the future of health care.
POSTER SESSION Glutathione S-transferase Genes and Coronary Artery Disease
Andreassi M.G.*, Botto N., Clerico A.
CNR Institute of Clinical Physiology, G. Pasquinucci Hospital, via Aurelia Sud-54100, Massa, Italy e-mail: andreas@ifc.cnr.it
Atherosclerosis is the leading cause of illness and death in Western societies. It is now clear that the disease is a result of a chronic fibroproliferative-inflammatory response of the arterial intima leading to the formation of atherosclerotic plaque. There is, however, a strong experimental evidence for a "mutation theory of atherosclerosis", underlining the similarity between atherosclerotic and carcinogenic processes.
Importantly, deletion or mutation of gene coding for enzymes involved in the metabolism of hazardous compound may be responsible for individual susceptibility to genotoxic factors, predisposing to the development of atherosclerotic diseases Our hypothesis was that glutathione S-transferase (GST) null M1 and T1 (GSTM1 and GSTT1) genotypes, which are involved in chemical detoxification, may modulate the risk for smoking-coronary artery disease (CAD). We assessed the distribution of the GST-genotypes in 430 patients angiographically-defined patients. We also examined the levels of DNA damage in CAD patients (n=66) by the micronucleus (MN) test, a sensitive assay for evaluating DNA damage. The frequencies of GST null genotypes were not significantly different between patients with CAD (n=308) and without CAD (n=122). However, relative to never smokers with GSTpresent genotypes, in non-smokers carrying both null genotypes the odds ratios (OR) of CAD was 0.66 (CI 95%= 0.3-1.5, p=n.s). In smokers with both present genotypes, the OR was p=n.s.) and was significantly increased in smokers with concurrent lack for GSTM1 and GSTT1 genes (OR= 4.0, 1.4-11.5 p=0.01). Smokers lacking GST genes had both higher number of stenosed vessels (χ 2 =7.8, p=0.046) and elevated Duke score (49.0±4.0 vs 38.0±3.7 p=0.048, p=0.048) as compared to smokers expressing the genes. MN levels were higher in smokers with null genes as compared to smokers with present genes (18.0±2.4 vs 7.5±1.9, p=0.02; 22.5±1.5 vs 6.0±1.7, p=0.007; for GSTM1 null genotypes and both null genes, respectively). These results suggest that the GST-null genotypes may strengthen the effect of smoking on CAD risk by modulating the detoxification of genotoxic atherogens. The family of cytochrome CYP450 consisting of more than 30 isoenzymes, is responsible for the metabolism of a large number of drugs and metabolites. One of these, CYP2D6 (debrisoquine 4-hydroxylase) is responsible for the metabolism of several drugs tricyclic anti-depressants, neuroleptic agents, β-blockers, antiarrythmics, selective serotonin reuptake inhibitors and opiates. Mutations in the CYP2D6 gene are responsible for altered enzyme activity and as a consequence, the patients exhibit adverse or inadequate response to therapeutic agents. The aim of this study was to determine the prevalence of the most common mutations of CYP2D6 gene (CYP2D6*3, CYP2D6*4) and to predict genotype frequency in Greek population. M Me et th ho od ds s: : We analyzed 38 non-related Greek subjects to determine the allele frequencies of CYP2D6*1 (wt -extensive metabolizers) CYP2D6*3, CYP2D6*4 (poor metabolizers) by PCR-restriction fragment length polymorphism (PCR-RFLP) method. R Re es su ul lt ts s: : Inactivating CYP2D6*4 mutations were detected in 12 subjects (2 of them were homozygous and 10 heterozygous). In 76 analyzed alleles, 62 had the wild type allele while 14 were mutant (18,4%). Regarding CYP2D6*3, we have analyzed 12 subjects so far without finding any mutated alleles. C Co on nc cl lu us si io on ns s: : Our results are in concordance with the other European populations, and the prevalence can be interpolated between the values of mid-Europeans and Mediterranean populations. More samples should be analyzed for the presence of CYP2D6 alterations in order to reach the statistical power necessary to make safe conclusions about the YP2D6 genotype frequency in the Greek population. Molecular genetic analysis constitutes a determinative tool for the definitive validation of the right dose to the right patient and we plan to incorporate in the near future CYP2D6 genotype analysis in the diagnostic services offered by our lab to the Academic hospital of Alexandroupolis. We prospectively evaluated the association between two polymorphisms in the CETP gene (TaqIB and Ile405Val) with lipid levels and the risk of fatal and non-fatal coronary heart disease (CHD). We further evaluated the proposed interaction between these gene polymorphisms and alcohol consumption. A case-cohort study was embedded in a population-based cardiovascular risk factor survey among 35,488 men and women followed for 9.3 ± 2.8 years. Genotypes were determined for all fatal (n=162) and incident non-fatal (n=350) cases with CHD and a random sample (n=1093) of the full cohort. Subjects with the CETP TaqIB B2B2 genotype had significantly higher HDL-cholesterol and ApoAI levels (1.39 mmol/l and 1.75 g/l, respectively) than subjects with the B1B1 or B1B2 genotype (1.25 mmol/l and 1.64 g/l, p<0.0001). HDL-cholesterol levels were increased in female carriers of the 405Val allele as compared to non-carriers (1.42 vs 1.35 mmol/l, p=0.01), but not in male carriers. No association between the TaqIB or Ile405Val polymorphism and the risk for fatal or non-fatal CHD was observed. Furthermore, alcohol consumption did not modulate our observations. In conclusion, although the CETP TaqIB and Ile405Val polymorphism are associated with a more favourable lipid profile, they have little impact on CHD risk, and do not interact with alcohol consumption.
Genotyping of Cytochrome P4502D6 Mutations in a Greek
Alcohol Consumption does not
Evidences of the Impact of Water Quality on Gel Electrophoresis
Bôle J., Mabic S.
MILLIPORE, St Quentin, France
Gel electrophoresis has been used for decades to detect the presence of gene sequences, monitor the gene expression, study protein profiles in cells and tissues, or isolate proteins for MALDI-TOF analysis. It is a necessary step in most genomic and proteomic studies, as well as in studies looking at the effect of drugs and environmental pollutants on gene and protein expression. While gel casting and elution protocols have long been established, the impact of the quality of the water used to prepare buffers was investigated, and was found surprisingly significant both on agarose and on polyacrylamide gel electrophoresis. Two-dimensional gel electrophoresis run using various types of water were compared using silver staining and Coomassie Blue coloration. From better migration in the first dimension to increased resolution and higher peak intensity, usage of high purity water clearly brought benefits over bottled water. The differences observed directly on the gels and after examination using gel analysis software (Melanie) were related to the organic content of the water using LC-MS. Organic molecules are suspected to interfere with the gel and the protein elution. Separation of PCR products were also compared using several types of water. Water quality was found to have an impact on the migration and on the intensity of the DNA bands (analysis with Quantity-One software). Series of gels will be presented to evidence the impact of water and relate the water contamination to the separation of DNA.
Homogenous SNP Genotyping Based on Restriction Endonuclease Cleavage
Bosia A., Amicarelli G., Bonanno C., Shehi E., Adlerstein D.* Diasorin SpA, via Crescentino snc, 13040 Saluggia (VC), Italy
The analysis of single nucleotide polymorphisms (SNPs) is increasingly utilized in the study of various genetic determinants. Here we introduce the OneCutEventAmplificatioN (OCEAN) reaction 1 , a simple, rapid, low cost and accurate procedure for the detection and quantification of DNA or RNA sequences. The system consists of a single tube isothermal amplification reaction based on the selective hybridization of two probes (an "amplifier" and an "anchor") to the specific target nucleic acid. The target-anchor duplex forms with the amplifier a ternary structure, which contains the recognition site for a restriction endonuclease. Digestion with the enzyme produces a cut amplifier, which then dissociates, while the duplex target-anchor is recycled in the reaction. The reaction results in a linear digestion of the amplifier, mediated by the target-anchor duplex. OCEAN assays have already been designed for various SNPs of diagnostic interest such as ApoE (C4070T and T3932C), PDK2 (C1358G), CKM1 (C18104T), coagulation Factor V (G1691A) and Prothrombin (G20210A). In the present study we compare OCEAN assay results for these systems to polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). 
Study of Apo E Genotypes in a Hypercholesterolemic Young Adults
Brito R.M., Raicar S., Lobato J., Mendes L., Veiga L. ). Hypercolesterolemia prevalence was 20.6% (female = 21.6% and male = 13.3%). The overweigh prevalence was 15.3% and 2.8% of them were obese (BMI>30 Kg/m 2 ). In individuals with hypercholesterolemia, genotyping for apo E was performed by real time PCR with specific TaqMan probes. Total cholesterol (CT), LDL cholesterol (C-LDL), HDLcholesterol and triglycerides (TG) were measured by enzymatic methods. Apo E genotypes frequencies were 72.2% for E3/E3 and 27.8% for E3/E4. The ε4 allele frequency was significantly higher in our group of hyper-cholesterolemia when compared with a healthy Portuguese population (2) It is widely recognized that the translation machinery is associated with cancer development. Somatic mutations and changes in gene expression patterns of initiation and elongation translation factors associated with cancer, have been described. In what concerns translation termination factors, no such study have been made. Moreover, it is known that some human diseases, including cancer, can be associated with trinucleotide repeat expansion. The human eukaryotic releasing factor 3 gene (eRF3/GSPT1), with multi-functional properties in eukaryotic cells, shows a short expansion of a GGC trinucleotide repeat, encoding a polyglycine tract in the amino terminal of the protein. The number of GGC repeats range from 7 to 12, being the allele with 10 repeats the most common in the Portuguese population. The aim of this work was to establish whether GGC repeat within eRF3/GSPT1 gene is associated with gastric cancer risk and specific tumor characteristics in the Portuguese population. The trinucleotide repeat was studied in a group of 139 individuals with gastric cancer and in a control population with 100 individuals. The results obtained showed that the distribution of GGC repeats is significantly different between these two groups (χ 2 =15,486, p=0,002). The main difference observed is the presence of allele (GGC)12 exclusively in gastric cancer population. A total of 8% (n=11) of individuals with gastric cancer had the (GGC)12 allele, compared to none in control population. Patients with this allele had an increased risk of gastric cancer (OD= 19, 933, 95%CI= 1, 94, p=0, 001) . Moreover, significant differences were observed in allelic frequencies between gastric adenocarcimnomas and mucocellular carcinomas (χ 2 =34,881, p=0,001), being the (GGC) 12 allele more frequent in the latter. Our results show, for the first time, a strong association between a polymorphic trinucleotide repeat, in one translation termination factor, and cancer development. The precise role of these repeats in gastric cancer is presently under study. The variability of plasma levels of drugs in patients treated with the same doses might be partly due to the polymorphism of cytochrome P450. CYP2D6 plays an important role in the metabolism of several commonly used antipsychotic and antidepressant drugs. We have found that CYP2C9*3 allele is related the risk of major depressive disorder, however CYP2C9 is a relatively new studied polymorphism. So far, the role of CYP2D6 and CYP2C9 genotypes during treatment under general clinical conditions has not been fully clarified. The present studies were aimed at evaluating the influence of CYP2D6, CYP2C9 on the analysed drug plasma concentration. CYP2D6 and CYP2C9 genotypes, debrisoquine metabolic ratio (MR) and drug and metabolites were determined among 64 patients treated on fluoxetine, 30 on haloperidol, 76 on thioridazine and 35 on risperidone monotherapy. Allele frequencies: The CYP2D6 and CYP2C9 allele frequencies found among schizophrenics were similar to those previously described among Spanish healthy volunteers, however different from depressive patients. Antipsychotics: The number of CYP2D6 active genes was related to the dose-corrected plasma concentration of thioridazine (p<0.01), and risperidone (p<0.05). The dosecorrected plasma concentration of haloperidol (p<0.05) and thioridazine (p<0.01) were related to MR. Fluoxetine: The dose-corrected plasma concentrations (p<0.01) and fluoxetine/norfluoxetine ratio (p<0.01) were related to CYP2D6 active genes. Among those with two CYP2D6 active genes, the dose-corrected plasma concentrations of fluoxetine and active moiety were related (p<0.05) to CYP2C9 genotypes. We did not found relationship between alleles frequencies and schizophrenia. According to the present data plasma concentrations of haloperidol, thioridazine, risperidone and fluoxetine might be higher (among CYP2D6 Poor Metabolisers) or lower (among Ultrarapids) than expected. The concomitant treatment with drugs metabolised by the same enzyme must be taken into consideration due to the potential risk of drug interaction and side effects (i.e. arrhythmias). Supported by Junta de Extremadura, Consejería de Sanidad y Consumo (Grants 2002 (Grants /48, 2003 and NIH (Grant GM61394). In recent years, RNAi has emerged as a powerful tool for the downregulation of specific genes in cultured cells. Significant progress has been made in dissecting the mechanism of action of the RNAi machinery responsible for specific silencing of target mRNA (1) . Rules for designing potent RNAi reagents have been developed (2) as well as approaches to minimize "off-target" effects of RNAi constructs (3). These advances have highlighted a major "bottleneck" remaining in robust application of siRNA for gene silencing. There remains a need for reliable, broad spectrum, transfection reagents for use both in vitro and in vivo. We designed and synthesized several novel lipid-peptoid conjugates (OptiFECTINs) that mediate siRNA transfection in a variety of cell lines with comparable to or greater efficiency than two commonly used commercial transfection reagents. Moreover, OptiFECTINs work well on difficult to transfect cell types, demonstrate low cytotoxicity and are used in the presence of serum. Cell lines used included, HeLa, HepG2, MCF-7, 293T, SK-n-SH (neuroblastoma), COS-7, PC-12, Hs27 and Huvec (primary endothelium). Screening of OptiFECTINs was carried out with a siRNA targeting Lamin A/C mRNA, transfection efficiency was measured by target RNA and protein reduction after 48-72 h treatment. Efficient transfection was achieved with several different OptiFECTIN formulations, notably OptiFECTIN 3 and 6 worked well in most cell lines. For example, in HepG2 cells treatment with 2 µg/mL of OptiFECTIN 3 or 6 and 30 nM Lamin A/C siRNA resulted in Lamin A/C RNA reductions of 75 and 80%, which corresponded to a reduction in Lamin A/C protein of 65 and 75%, respectively. Similar transfection efficiency was achieved in other cell lines with OptiFECTIN 3 and 6. Currently, additional OptiFECTIN formulations are being developed and optimised for in vivo delivery. Human mismatch repair genes include homologs of the Escherichia coli mutS -hMSH2, hMSH3, hMSH6 -, and mutL homologs -hMLH1, hMLH3, hPMS1, and hPMS2. The mutation of MMR genes are associated with hereditary nonpolyposis colorectal cancer, and several malignancies. A substantial fraction of sporadic cancers including lung, colon, prostate, breast, bladder, ovary, head and neck have exhibited the microsatellite instability. The aim of this study is to identify the allele frequency of SNPs of the mismatch repair genes in the Korean population and to identify novel SNPs of the genes. Sixty seven SNP sites from the mismatch repair genes were either collected from the NCBI's SNP database or newly found in the Korean population and the allele frequencies were examined. Allele frequency of 67 SNP sites from seven mismatch repair genes was estimated in the DNA pool of 120 korean people [1, 2] . And the SNP sites with minor allele frequency of more than 0.1 were examined by sequencing in 120 individuals. They were 51 known SNPs and 16 novel ones. The SNPs of 3' UTR was 3, 5' flanking region 16, coding sequence with non-synonymous mutation 37, coding sequence with synonymous mutation 5, and intron 5. Allele frequency of Korean was compared with that of North American. Out of 67 SNPs, allele frequency of North American was available in 27 SNPs. The difference of allele frequency was more than 10% in 3 cases (11.5%). The allele frequency was different between Korean and North American. Our results will be used for comparative studies of the human population for disease association studies and in scanning candidate disease genes for DNA mutations versus polymorphisms. Preeclampsia is known as one of the most serious and relatively common complications of pregnancy 1 . A lot of data so far have demonstrated possible associations between preeclampsia and genetic polymorphisms related to hypertension 2 . An Alu polymorphism (I/D) of the angiotensin-converting enzyme (ACE) gene plays an important role in blood pressure regulation. Repeat polymorphism (4a/4b) of the endothelial NO-synthase (eNOS) gene is also associated with vascular tone maintenance. An important role in the regulation of fibrinolytic activity and blood pressure is played by plasminogen activator inhibitor type 1 (PAI1) and tissue plasminogen (PLAT) activator. Polymorphisms of corresponding genes (4G/5G of the PAI1 promoter and I/D of the PLAT) are associated with elevated or decreased activity of the relevant gene products. The DNA samples from 117 women with preeclampsia (patients) and 79 healthy parturient women (control group) were studied by PCR-RFLP assay for all polymorphisms. The frequencies of 4G/4G genotype of the PAI1 (45%) and I/I genotype of the ACE () genes in patients were signi-ficantly higher than in control group (p<0.05, 30% and ), because of the frequency of I/I genotype in subgroup with essential hypertension (p<0.02). Also the frequency of 4b/4b genotype of the eNOS gene in subgroup with severe uncomplicated preeclampsia was significantly higher as compared to controls (p<0.01). No differences were registered between genotypes and alleles distribution in I/D polymorphism of the PLAT gene. The presence of 4G/4G genotype of the PAI1 gene suspected to be a risk factor for the development of preeclampsia. We have found that I/I genotype of the ACE gene is associated with essential hypertension but not with preeclampsia. The debrisoquine metabolic ratio (MR) has been used widely to determine the hydroxylation capacity of the polymorphic cytochrome P450 enzyme CYP2D6. However the relationship between CYP2D6 active genes and the enzyme hydroxylation capacity has not been clarified in Spanish healthy volunteers including poor (PMs) and ultrarapid metabolizer (UM) subjects (1). Previously we reported a high number of very fast subjects among Spaniards (2) . The aim of the present study was to evaluate debrisoquine MR in a panel of sixteen White Europeans healthy volunteers with 0 (PMs), 1, 2 or more than two 2 (UMs) active CYP2D6 genes. The development of a simple, precise highperformance liquid chromatography method using ultraviolet detection for the determination of debrisoquine and 4-hydroxydebrisoquine in the human urine was also aimed. The number of CYP2D6 active genes was related to debrisoquine MR (p<0.05). For the determination C 18 extraction column was used and detection wavelength at 210 nm.
CYP2D6 and CYP2C9 among Patients Treated with
Polymorphism of Vascular
References
Coefficients of variation at all concentrations were less than 6% for both compounds. The limit of quantitation was 0.24 mg/ml for both compounds.
A good correlation between the number of CYP2D6 active genes and the hydroxylation capacity of the enzyme determined by debrisoquine MR has been shown. The method proves to be simple, fast and accurate to evaluate CYP2D6 hydroxylation capacity.
Department of Medicine, Toronto General Hospital and University of Toronto, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada
The influence of genetic variants on the HDL-C response to fenofibrate treatment was evaluated in a subgroup of T2DM subjects from the Diabetes Atherosclerosis Intervention Study (DAIS). The CETP Taq1B, LPL-S447X, LIPC, PPARA L162V and G/C intron 7 polymorphisms and the Apolipoprotein E2/E3/E4 alleles were genotyped in the subjects randomised to fenofibrate treatment (200 mg/day) for at least 3 years, using PCR and restriction enzyme digestion. Based on their relative elevation of HDL-C after treatment, subjects were divided into strong responders (∆% ≥ 7% corresponding to the mean relative elevation observed in the fenofibrate group in DAIS) and weak responders (∆% < 7%). Percentage distribution of strong and weak responders according to their genetic polymorphisms were compared by Chi 2 test, or Fisher's exact test when appropriate. Stepwise logistic regression was used to identify the significant predictors of HDL-C response among baseline HDL-C, the genetic polymorphisms and subject characteristics (age, gender, BMI, smoking status). Baseline HDL-C level, BMI, smoking status, and only the CETP Taq 1B polymorphism were selected in the model (significant level for entrance = 0.05) as significant predictors of response to fenofibrate treatment. Odds ratio estimates were 4.13 (95%CI 1.33-12.84) for B1B1 vs. B2B2, 0.89 (0.79-1.00) for each 1 Kg/m² baseline BMI, 0.21 (0.07-0.65) for current vs. non-smokers, 0.92 (0.87-0.97) for each 1 mg/dL baseline HDL-C level. The results indicate that baseline HDL-C levels, and additionally the presence of the B1B1 variant in the CETP gene were associated with HDL-C response to fenofibrate treatment in T2DM subjects.
Association of CYP2A6*1B Genetic Variant with the Amount of Smoking in French Adults from the Stanislas Cohort
Gambier N. Genetic variations of CYP2A6 alter nicotine metabolism. This study was developed to investigate the genetic influence of the polymorphism of CYP2A6 on the active smoking behavior. 463 French adults included in the Stanislas Cohort were genotyped by RFLP for the CYP2A6*1A allele and the CYP2A6*1B and CYP2A6*4 variants of CYP2A6. Informations about active smoking status were obtained by a self administered questionnaire. Genetic influence of CYP2A6 polymorphism on smoking behavior was evaluated using a stepwise multiple regression analysis. The frequencies of the CYP2A6*1A, CYP2A6*1B and CYP2A6*4A alleles were 64%, 32% and 4% respectively. 47 individuals were homozygous for the variant CYP2A6*1B (18 never-smokers, 13 smokers and 16 ex-smokers). 181 individuals were homozygous for the CYP2A6*1A allele (71 neversmokers, 61 smokers and 49 ex-smokers). The number of cigarettes smoked per day was significantly higher in the CYP2A6*1B/*1B group compared to the CYP2A6*1A/*1A group (p=0,02). The subjects with CYP2A6*1B allele were reported to have higher capacities of cotinine formation from nicotine than subjects with CYP2A6*1A. Thus the CYP2A6*1B/*1B nicotinedependent individuals might need a higher number of cigarettes smoked per day to maintain nicotine levels in their brain.
Myosin Binding Protein-c Gene Analysis by DHPLC: Novel Mutations and Prevalence of Compound Heterozygosis Associated with Hypertrophic Cardiomyopathy
Girolami F. We studied the clinical and genetic features of hypertrophic cardiomyopathy (HCM) caused by mutations in the Cardiac Myosin-Binding Protein C gene (MYBPC3) gene in a regional population in Central Italy. HCM is an autosomal dominant disorder characterized by unexplained left ventricular hypertrophy, usually asymmetric and involving the interventricular septum. More than 200 mutations in ten different genes encoding sarcomere proteins have been identified in HCM patients. All 35 exons of MYBPC3 were screened by DHPLC followed by automatic sequencing in 124 consecutive, unrelated patients with HCM. The diagnosis was based on two-dimensional echocardiographic identification of a hypertrophied, non dilated left ventricle, in the absence of another cardiac or systematic disease capable of producing the magnitude of wall thickening evident. Overall, we identified 22 MYPC3 mutations in 19 patients (a 15% prevalence). Fifteen mutations (68%) were novel (IVS18+1C>T, A522T, V771M, E165D, ins/del exon 25, V189I, G531R, D786Y, R273H, E334K, R470W, Y340X, A693S, IVS12+1G>A, IVS24-2A>G) and not detectable in 100 normal controls, thus excluding the possibility of polymorphisms; three patients (16%) had two mutations affecting MYPC3, a condition termed compound heterozygosis; specifically, these were A522T with V771M, E334K with R470W, and D786Y with A693S. Echocardiographic features and outcome were variable, and ranged from mild hypertrophy with total lack of symptoms to severe hypertrophy with severe outflow obstruction, to end-stage progression, to cardiac arrest. Of note, evidence of systolic impairment (ejection fraction <0.50) was present in a high proportion of patients (n=5, 23%; p<0.05 versus the overall study group). In a regional HCM population from Central Italy, MYBPC3 mutations were common (15% of unrelated patients) and had different mechanisms (missense, nonsense, insertion/deletion, splice-site). Most of the mutations were novel including those found in the three patients with compound heterozygosis. The investigations of human genetic polymorphism are widely spread today, but studied groups mostly include patients with multifactorial diseases. To our mind the investigations of conditionally "healthy groups" like long-livers, athletes and newborns are not less important. In present study the following groups of subjects from North-West region of Russia were analysed: group1-population controls (121 subjects); group2-individuals elder than 70 years (147); group3-rowers from combined team of Saint-Petersburg (57). The polymorphisms of five genes (I/D-ACE, M235T-AGT, A1166C-AGTR1, 4a/4b-eNOS, 677C/T-MTHFR,) associated with some multifactorial diseases were studied by PCR-RFLP analysis. Distribution of genotype frequencies of AGT gene was different in three groups. Some increase of T/M genotype could be traced as following: population-athletes-elderly people (34%, 46% and 72%, respectively). Significantly higher frequency of T/M genotype was found in group2 compared to the group1 (T/M -72% and 34%, respectively; p<0.01) for the men only. Significant increase of C-allele of AGTR1 genes in the elderly women compared to population group was found (40% and 15%, respectively; p<0.001). The men from group1 had significantly higher frequency of C-allele of AGTR1 gene compared to the women (30% and 15%, respectively; p<0.01). Distribution of genotypes and alleles in eNOS gene was also different in the studied groups. Significant decrease of 4b allele was registered in the group2 compared to the group1 (64% and 80% respectively; p<0.01). The frequencies of genotypes and alleles of MTHFR and ACE genes did not differ significantly between the studied groups. However our results showed a decrease of frequency of genotypes D/D and I/I in elderly people compared to population frequency of these genotypes. It might be speculated that T/M genotype of AGT gene for men, C-allele of AGTR1 gene for women and 4b allele of eNOS has provided some inherited advantages for physical efficiency and longevity. Large-scale population studies of genetic predisposition as well as the screening of polymorphic loci associated with an individual drug sensitivity demand to create an effective, precise and fast method for the detection of many mutations simultaneously. From our point of view, the most perspective method to solve problem, is hybridization on oligonucleotide microarrays (microchips). Thus, our goal was to develop and manufacture a biochip ("Pharmagenchip") for polymorphism detection of biotransformation system genes. The following loci have been chosen: CYP1A1 (C4887A, A4889G and T6235C), CYP2D6 (G1934A and DelA2637), GSTM1 (deletion), GSTT1 (deletion), NAT 2 (S1, S2, S3 alleles), CYP2C9 (C430T and C61075T), CYP2C19 (G681A), NQO1 (C609T) and MTHFR (C677T). We have used multiplex PCR with subsequent hybridization on the biochip as polymorphism detection method. Principal novelty of the approach is that the designed biochip consists of blocks of genes (from 2 up to 5 mutations on each block). Depending on the field of investigation, the researcher can combine blocks at designing the diagnostic biochip for the analysis of concrete disease or a certain physiological status, and also to change genes inside the block. In parallel, some multiplex asymmetric PCR reactions (their number was defined by quantity of blocks) with fluorescence primers were carried out. We mixed products of the reactions and carried out multiplex hybridization on biochip. Mutations were discriminated by analyzing fluorescence intensities from separate units on the biochip. By analyzing mutations in genes CYP1A1, CYP2D6, GSTM1, GSTT1, NAT 2, CYP2C9, CYP2C19, NQO1 and MTHFR, we have shown the efficiency of the approach for SNP identification in human genome. We believe that using of "Pharmagenchip" would become the convenient tool for pharmacogenetic research. Cooperation Unit Pharmacogenomics/Applied Genomics, University of Heidelberg, Germany B Ba ac ck kg gr ro ou un nd d: : Factor VII (FVII) levels are influenced by the R353Q and the -323 (0>10) polymorphism of the FVII gene. The substitution of glutamin for arginine at position 353 and the 10 bp insertion in the promotor at -323 are both associated with 20-30% lower plasma FVII levels. Furthermore, strong allelic association was observed between the two polymorphisms. Therefore we formed haplotypes and measured FVII levels in white male and female individuals with and without coronary artery disease, who had undergone a coronary angiography in order to provide genotype specific FVII reference intervals for white Caucasians. M Me et th ho od ds s: : Study participants were 3304 white patients hospitalized for coronary angiography between June 1997 and May 2001 from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. FVII levels were measured out of citrate plasma by a chromogenic substrate assay. Genomic DNA was prepared from EDTA anticoagulated blood and FVII genotypes were determined by PCR-based methods. R Re es su ul lt ts s: : The haplotype containing the 353R and the 0 bp variant at -323, designated as Hap1, was the strongest predictor of FVII levels in a multivariate regression model in subjects without coumarin and heparin medication. FVII levels were significantly associated with the number of Hap1 alleles (p<0.0001). Individuals with one Hap1 allele had 15% higher FVII levels and individuals with two Hap1 alleles had 30% higher FVII levels than individuals with no Hap1 allele. The number of subjects with 0, 1 or 2 Hap1 alleles were 60, 829 and 2415, respectively. C Co on nc cl lu us si io on n: : FVII levels strongly depend on the FVII haplotype with values that increase with the number of Hap1 alleles. Genotyping of the FVII gene may be useful in order to allow a more precise interpretation of FVII levels.
Analysis of ACE, AGT, AGTR1, ENOS, MTHFR Genes Polymorphisms in the Elderly
DrugMEt
™ Genotyping Microarray for the Major Drug Metabolising Enzymes
Hendolin P.H.*, Ristonmaa U., Liikola A., Kolu P., Aalto J.M., Korhonen V.P.
Oy Jurilab Ltd-P.O.Box 1188, Microkatu 1, 70211 KUOPIO, Finland In recent years, the inclusion of pharmacogenetic testing in clinical trials has gained interest. The advancement in microarray-based methods provides the capacity for genotyping several SNPs in many samples simultaneously. The Jurilab DrugMEt ™ test is based on on-chip allele-specific extension. It targets 27 SNPs from eight drug-metabolising enzyme genes with a proven role in the metabolism of major drugs: CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5, TPMT, NAT2, and MDR1. The test consists of an array-of-arrays for 16 samples. Each SNP is analysed with a pair of allele-specific primers that are printed within the array in duplicate. The results are assessed with proprietary SnpRater™ soft ware. In addition, the test includes a separate multiplex PCR for the detection of CYP2D6 duplication and deletion. The performance of the assay was studied internally for accuracy, intraassay reproducibility, and in comparison to an alternative method. Transgenomic Inc., Business Development, Berlin, Germany B Ba ac ck kg gr ro ou un nd d: : Associations between circulating concentrations of E-selectin, blood pressure and obesity, and between the Leu554Phe (L/F554) polymorphism and blood pressure have been documented. O Ob bj je ec ct ti iv ve es s: : To investigate how the E-selectin L/F554 polymorphism is involved in longitudinal blood pressure changes, and how this polymorphism interacts with body mass index (BMI) on blood pressure. D De es si ig gn n a an nd d p pa ar rt ti ic ci ip pa an nt ts s: : For this study, 478 men and 546 women were selected from the Stanislas cohort, a French longitudinal study of volunteers for a free health check-up. These individuals underwent two examinations (t0 and t5) and were not taking medication that can affect blood pressure. R Re es su ul lt ts s: : At t0, no relationship was observed between L/F554 polymorphism and blood pressure. However at t5, systolic blood pressure (SBP) was greater in individuals carrying the F allele, and the L/F554 polymorphism was associated with SBP in interaction with BMI (P < 0.001 in men and P < 0.05 for women). There was a steeper increase in SBP with BMI greater than 25 kg/m 2 in carriers of the F allele than in LL homozygotes. Similar results were observed for diastolic blood pressure in men (P 0.0103). C Co on nc cl lu us si io on n: : These results suggest a BMI-specific effect of L/F554 polymorphism of the E-selectin gene on blood pressure, and strengthen the hypothesis that E-selectin is implicated in hypertension. P-selectin is an adhesion molecule known to be involved in the pathogenesis of several diseases through its major role in the initial phase of leukocyte recruitment during inflammation. The aim of this work was to study the familial correlations of P-selectin levels and to investigate the associations between S290N, V599L and T715P P-selectin polymorphisms and P-selectin concentrations in a sub sample of 175 healthy families of the STANISLAS cohort.
P-selectin Serum Concentrations in the Stanislas
Accounting for the effect of covariates (age, sex, oral contraceptive use, leukocyte, erythrocyte and platelet counts, glucose and TNF-alpha concentrations) the two polymorphisms V599L and T715P were significantly related to P-selectin concentrations in both children and parents, whereas no significant effect was noticed for S290N polymorphism. V599L and T715P, in strong linkage disequilibrium (D' = -0.99), independently influenced P-selectin concentrations, accounting for 9.9% and 18.9% of variability with allelic effects of -26.5 and -39.4 mg/L, respectively. Family correlations of P-selectin concentrations were of similar magnitude for sibling (0.489) and child-parent pairs (0.465), and were higher than between parents (0.173). After adjustment for these 2 polymorphisms, sibling and child-parent correlations decreased to 0.387. In this study, we showed that P-selectin concentrations were significantly correlated within genetic-related relatives and that V599L and T715P polymorphisms partly explained this family aggregation. It is well known that obesity is a condition resulting from the chronic imbalance between energy intake and energy expenditure, with weight gain as the main consequence 1 . The hypothalamus plays a major role in the control of energy homeostasis in the body. To identify the obesity-related genes in the hypothalamic area, the microarray analysis was performed between the control and the ob/ob or fasting mice. The genetic expression was compared using a 7.4-K cDNA microarray. The PGC-1 was selected from the result, which was under-expressed in fasting mice and overexpressed in ob/ob mice. The PGC-1 is known to be involved in the gluconeogenesis and lipid metabolism. 2 In light of the results of the microarray and RT-PCR analysis, further genetic study of the PGC-1 gene was carried out. PGC-1 possesses a polymorphism in the form of Thr394Thr (exon 8, rs3755863, G/A), which is known to be associated with insulin resistance and susceptibility to type II diabetes 3 . Cac8I RFLP analysis was performed to identify the Thr394Thr (G/A) genotypes in 92 obese women, 75 overweight women, and 95 non-obese controls. However, the genotype distribution and allele frequency have not significantly different between the obese or over weight women and the controls.
The genetic makeup determines inherent pharmacokinetics, giving rise to interpersonal differences in absorption, distribution, metabolism, and excretion of drug. The aim of this study is to evaluate the relationship between the genetic polymorphisms of CYP2D6*10 allele and risperidone hydroxylation in healthy male Korean subjects. 498 subjects were genotyped for the CYP2D6*10 allele. The frequencies of CYP2D6*1/*1, *1/*10 and *10/*10 were 27, 47 and 27%, respectively. Subjects were categorized into flollowing 3 groups (*1/*1, n=9;*1/*10, n=13; *10/*10, n=13) and risperidone (Risperdal® tablet, 2mg) was administered orally once to each group for bioavailability study. The pharmacokinetic parameters of risperidone and 9-hydroxyrisperidone were determined. AUC and T ½ of risperidone were significantly different among the *1/*1, *1/*10 and *10/*10 (p<0.001), but C max was not. And C max of 9-hydroxyrisperidone was significantly different among 3 groups (p=0.047).
High rates of hepatocellular carcinoma (HCC) in The Gambia, West Africa, are due primarily to a high prevalence of chronic hepatitis B virus (HBV) infection and heavy aflatoxin exposure via groundnut consumption. We investigated genetic polymorphisms in carcinogen-metabolizing (GSTM1, GSTT1, HYL1*2) and DNA repair (XRCC1) enzymes in a hospital-based casecontrol study. Incident HCC cases (n=216) were compared to frequency-matched controls (n=408). The prevalence of variant genotypes was generally low, but in multivariable analysis, the GSTM1-null genotype (OR 2.45: 95% CI, 1.21-4.95) and the heterozygote XRCC1-399 AG genotype (OR of 3.18: 95% CI, 1.35-7.51) were significantly associated with HCC. A weak, non-significant association of the HYL1*2 polymorphism and no association of GSTT1 with HCC was observed. The risk for HCC with null GSTM1 was most prominent among those with higher groundnut intake (OR, 4.67: 95% CI, 1.45-15.1) in comparison to those with lower groundnut consumption (OR, 0.64: 95% CI, 0.20-2.02). Among participants who had all three suspected aflatoxin-related high risk genotypes [GSTM1 null, HLY1*2 (HY/HH), and XRCC1 (AG/GG)], a significant 15-fold increased risk of HCC was observed, albeit with imprecise estimates (OR 14.7: 95% CI, 1.27-169). Our findings suggest that genetic modulation of carcinogen -metabolism and DNA repair can alter risk for HCC, and that these effects may be modified by environmental factors.
CYP2A6 Gene Polymorphisms and Smoking Behaviour
Köppel H., März W., Ramschak-Schwarzer S., Wascher T.C., Renner W.* The nasopharyngeal carcinoma (NPC) is a malignant tumor of multifactorial etiologies. The involvement of major histocompatibility complex (MHC) in NPC pathogenesis was previously demonstrated in the literature. Several studies suggested that particular HLA genes are considered as risk factors for NPC. The aim of our study is to determine HLA suspectibility markers which could be involved in NPC predisposition of south Tunisian patients and to compare HLA / NPC associations in south Tunisia with the literature. Thus, 110 NPC patients and 121 controls were typed for HLA class I by microcytotoxicity method. Fourty-Two out of 110 patients were genotyped for HLA class II by molecular biology (PCR-SSP) as compared to 112 controls. Our results showed that frequencies of HLA-A29 antigen and DRB1*03 allele were significantly higher in patients (X² = 4.367 and X² = 5.775 respectively) indicating positive associations with NPC. Contrarily, HLA-A26 antigen was not found in patients and was expressed in 7.43% of controls (X² = 6.584). The HLA-A23, -B14, -B35 antigens and DRB1* 01 allele were significantly less expressed in patients when compared to the control subjects (X² = 8.993 ; X² = 6.188 , X² = 4.694 and X² = 5.412 respectively) which suggested a protective role against NPC development. Alpha 1-antitrypsin (A1AT) deficiency is a genetic disorder characterized by a decreased A1AT level in plasma and a high risk of pulmonary emphysema and a liver disease at a young age. The most common mutation leading to A1AT deficiency is called Z due to the slow mobility in electrophoresis, which causes a loss of the internal salt bridge between two amino acids, Gly342 and Lys290, of the A1AT molecule (1) . The highest frequency of mutation Z was found in ethnic Latvians (2). Smoking is the major factor influencing the course of disease, because of oxidation of methionine residues, which interferes with complex formation of A1AT with elastase. Objective of the study was to detect A1AT deficiency types and oxidative status in adult patients with Chronic Obstructive Pulmonary Disease. SERPINA1 gene locus was first amplified by PCR (3), digested with restriction enzyme Taq1 and incubated for 120 minutes at 65°C. Evaluated correlation between genotype, oxidative status in plasma and lung functional tests. A1AT levels and lung functional tests significantly differed in patients with SERPINA ZZ genotype. Non-smoking patients with 10 fold decreased A1AT levels had 50% decrease of FEV1 and non-smoking patients with a long time exposure to dust had only 27% of normal FEV1. A1AT and FEV1 levels in smokers had been dependent of smoking status in years. We have investigated the HLA class I et II polymorphism in 76 unrelated and randomly selected healthy individuals originating from south Tunisia. We have studied the allelic distribution of HLA-A; B; C and DR/DQ by PCR-SSP. The HLA-A allelic distribution showed that the highest frequencies were of HLA-A2 and HLA-A1 alleles (f =15.7% and 11.8% respectively). At the HLA-B locus, HLA-B44 was the most frequent allele expressed in our population (f=11.8%), whereas HLA-B53 and HLA-B72 were the rare ones. For HLA-C: HLA CW07 was the main allele represented in this study (f = 17.7%). Finally, the HLA class II typing results showed that HLA-DRB1*07 and HLA-DQB1*02 were the predominant markers in our population (f = 15.1%, f = 26.3% respectively). When compared to other studies in the literature, our population seems to share allelic distribution similarities with Arabs and Caucasians. In conclusion, HLA specificities of the south Tunisian population may reflect the ethnical diversity of this community. Intracellular adhesion molecule-1 (ICAM-1), a cellular adhesion molecule that mediates the interaction of activated endothelial cells with leukocytes, is involved in various inflammatory and cardiovascular disorders. The relation between these markers and genetic polymorphism, however, remains to be elucidated. The aim of this study is to estimate the effect of a single-base polymorphism at codon 241 in exon 4 of ICAM-1 gene on serum sICAM-1 concentration in a healthy population, taking into account other biological determinants of sICAM-1 level. Serum sICAM-1 levels and the G/R241 polymorphism of the ICAM-1 gene were measured in a large healthy population consisting of 413 children aged 6-21 years and 363 adults aged 38-55 years extracted from the Stanislas cohort. The R241 allele was significantly associated with lower sICAM-1 levels and explained 3.4 and 1.9% of the sICAM-1 variability in children and adults, respectively. A codominant pattern contributed better to the model after adjustment for covariates as the RR homozygote effect was higher than that of the GR heterozygote. Moreover, significant independent associations were found between sICAM-1 and smoking, insulin resistance index (HOMA IR), interleukin-6 level, and alkaline phosphatase and aspartate aminotransferase activities. In conclusion, this study revealed a significant association between the G/R241 ICAM-1 polymorphism and serum sICAM-1 levels, probably due to the impairment in binding of ICAM-1 to leukocyte integrin Mac-1 protein. GST (Glutathione S-transferase) family of enzymes plays important roles in detoxifying xenobiotic compounds by transferring soluble glutathion moiety to a variety of electrophilic compounds [1] . Polymorphisms in GSTm1 and GTSt1 have been associated with an increased risk for developing various neoplastic diseases [2] . However little is known about the relationship between these polymorphisms and susceptibility of leukaemia. In this study we hypothesize that genetic variations in GSTs and other detoxifying enzymes could be a risk factor of leukemic disease, especially AML (Acute myelogenous leukemia). In order to test this hypothesis we designed a case-control study on AML by genotyping DNA samples from normal (n=144) and AML cases (n=192). Also we tested 5 SNPs as markers for a molecular epidemiological study from three different genes, methylenetetrahydrofolate reductase (MTHFR), NAD(P)H dehydrogenase and CYP2A7. Each exon including the SNP site with flanking exonintron boundary was amplified by PCR and genotyped to measure its frequency. All of five SNPs were in HardyWeinberg equilibrium suggesting there was no sampling error. Out of five SNPs, rs1051740 of microsomal epoxide hydrolase showed slightly higher frequency of T allele in patient group and lower C allele frequency with OR 1.34 (95% CI = 0.99-1.85). We report here that GSTt1 deletion has been shown to be associated with increased risk for developing AML with OR 2.00 (95% CI = 1.25-3.13).
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Somatic mosaicism refers to the presence of genetically distinct clonal populations of somatic cells within an organism and can be caused by DNA mutations, epigenetic alterations of DNA and chromosomal abnormalities. Both Mendelian and non-Mendelian disorders are associated with somatic mosaicism, with the most studied examples of being found in the pathogenesis of cancer. The failure to identify mutations associated with somatic mosaicism can lead to inaccurate reporting of mutation frequencies and missed genetic diagnoses. These considerations are also very apparent in the detection of somatic mutations in cancerous tissues and disease-causing mutations in heteroplasmic mitochondrial DNA. This report describes a thorough approach for the identification of somatic mosaicism that combines the simplicity of Surveyor mismatch endonuclease technology with the high sensitivity detection capabilities of the WAVE-HS nucleic acid fragment analysis system. Surveyor nuclease mutation detection is based on an enzymatic method for detecting DNA heteroduplexes and can be used to detect both known and unknown mutations including all base substitutions as well as insertions and deletions. The WAVE-HS System utilizes postseparation fluorescent dye intercalation for the high sensitivity detection of nucleic acids. By combining these two technologies, we were able to scan efficiently a large number of genes for somatic variations within different patient cohorts. Examples will be presented in which somatic mosaicism was identified with this in-depth scanning approach; these include mutations in genes encoding drug targets, transporters, and signal transduction effectors. This approach was also used to the scan of mitochondrial DNA. This report will demonstrate the detection and identification of somatic genetic variants that are below 1% of the total alleles present, and present prior to any chemotherapeutic treatment. These somatic mutations, which result in functional aberrations within the coding regions of the analyzed genes, were not detectable using traditional mutation detection approaches, such as DNA sequencing.
Efficacy of Anti-obesity Therapy among Carriers of the Gln27Glu Beta2 Adrenoreceptor Gene Polymorphism.
Study in Polish Caucasians with Familial Obesity
Malczewska-Malec M., Wybranska I., Niedbal S., Szopa M., Partyka L., Glab G., Leszczynska-Golabek I., DembinskaKiec A.* Department of Clinical Biochemistry, The Jagiellonian University Medical College, Kopernika 15A, PL-31 501 Krakow, Poland O Ob bj je ec ct ti iv ve e: : To investigate whether the Gln27Glu polymorphism of the beta2adrenoreceptor (BAR2) gene contributes to differences in efficacy of anti-obesity therapies (diet and physical training). M Me et th ho od ds s a an nd d P Pr ro oc ce ed du ur re es s: : A total of 50 women (age: 32+/-6,8 year old) with no serious clinical symptoms of disease except obesity, recruited from families with familial trait of obesity participated in the three month intervention study using diet or diet and adjusted to 60% of VO 2max exercise programs. BAR2 genotype was determined in DNA harvested from peripheral blood cells by polymerase chain reaction followed by ITA I digestion. (RFLP method.) Anthropometrical measurements (weight, height, percent of body fat) and biochemical measurements (serum level of cholesterol, triglyceride, glucose, insulin, leptin) during OGTT and OLTT (oral lipid tolerance test(pastprandial lipemia)) were performed at the beginning and after therapies. R Re es su ul lt ts s: : The frequency of the Glu27 allele did not significantly differ in the obese (58%) versus lean (68%) patients, however was frequent in patients with the higher valkue of DELTA index. At the baseline the BMI, body weight, body fat, or blood lipids and glucose profiles, not significant differ in obese subjects with, comparing without the mutated Glu27 allele carriers. The intervention with diet yielded a triglyceride reduction and induced a significant decrease in BMI (-6,31); total cholesterol (-8,89) , HOMA (-17,34) ; for women without the Glu27 allele. However the Glu27 allele carriers benefited more after combined: diet plus physical training therapy (significant decrease of percentage of body fat, blood triglyceride leptin levels, the sensitivity to insulin measured by HOMA and DELTA indexes were not improved. C Co on nc cl lu us si io on n: : The presence of mutated Glu27 allele of Gln27Glu BAR2 polymorphism promote mutated allele carriers to be more sensitive for the combined: diet plus physical training obesity treatment. It seems however not to be accompanied by the improvement of glucose tolerance. Thus the preventive therapy by increased physical training should be specially recommended for prevention/benefit of obesity treatment in BAR2 Glu27 allele carriers. Knowledge Discovery in Databases (KDD) is the analysis of large sets of observational data to find unsuspected relationships and to summarize the data in novel ways that may be both understandable and useful. Data mining is the central step of the KDD process, where algorithms are run for extracting the relationships and summaries derived through the KDD process and referred as models or patterns [1] . We aimed to identify new interactions in the domain of lipid genetics by using an approach combining Data Mining and Statistics. The population studied consisted of 772 men and 780 women from the STANISLAS cohort [2] . The data mining methods used in our experiments were based on the Close algorithm for extracting closed frequent patterns and association rules [3] . After a preliminary work on the whole genetic biological and clinical data, we focused on sub samples related to APOB and APOE genes. The corresponding rules suggested hypotheses validated by Statistics. In men, a significant interaction was found between an environmental factor and APOBThr71Ile polymorphism on LDL-cholesterol concentration. In women, we detected an interaction between APOE and APOB genes suggesting a potential protective genetic profile. In conclusion, our results highlight the importance of considering interactions involving lipid metabolism genes when studying markers of cardiovascular diseases. This is an original and promising way of combining data mining methods and statistics. We are currently working on this combination and we plan to obtain a general methodology for mining biological data and establishing new potential disease susceptibility profiles.
Recent years have brought dramatic changes in the treatment of breast cancer (BrCa), primarily based on the elucidation of pathogenetic mechanisms at the molecular level. One of the hallmarks was the introduction of the monoclonal antibody trastuzumab (Herceptin) for the treatment of Her-2/neu positive BrCA, representing 20-30% all cases. Therapeutic decisions are taken based on determination of the Her-2/neu status of a given tumour, tested either by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH). There has been mounting evidence from a number of clinical trials that FISH has diagnostic accuracy superior to standard IHC. Accordingly, FISH is rapidly gaining acceptance as a primary testing tool. A DNA probe set developed to coidentify chromosome 17 (17p11.1-q11.1 CEP17 centromeric alpha-satellite) and amplification of the Her-2/neu gene (17q11.2-q12 LSI) is now being widely used to make treatment decisions. In addition to documentation by other studies, the advantages of that approach have been convincingly documented in a preliminary analysis of the ongoing BCIRG006 trial (first 2,600 specimens) demonstrating a high false negative rate (>20%) in IHC 3+ patients, all correctly identified by FISH (Press et al. 2003) . In contrast to earlier reports using IHC alone it was also shown that up to 10% of IHC 1+/ FISH +ve patients responded to Herceptin. Another target sequence of the 1p12 region of chromosome 17, relevant for BrCA diagnostic testing and in close proximity telomeric to the Her-2/neu locus, relates to the topoisomerase II (TOPO) located at 17q21-q22. TOPO, a key enzyme in DNA replication, is the molecular target for many inhibitors including the anthracyclines (AC), one of the backbones of modern chemotherapy of BrCA. It has been reported-in a limited number of patients-using a 473 kb FISH probe spanning the TOPO gene sequence that amplification is found in approximately 20% of all Her-2/neu +ve cases and that these pts. -unlike TOPO negatives-have a high probability of responding to AC treatment (Järvinen et al. 2001 , Di Leo et al. 2002 . The hypothesis of employing TOPO as a differentiating marker for AC therapy is being further tested in a large prospective European trial enrolling >5,000 patients. In conclusion, the development of standardized, highly reproducible FISH testing has led to significant improvement in the management of breast cancer patients worldwide. In addition, FISH probes in development are likely to open new opportunities for selecting appropriate treatment regimens for a variety of other cancers, such as lung, esophagus and cervical Ca. Humans are exposed to a number of reproductive toxicants. Nevertheless, not all women who are exposed have adverse reproductive outcomes. It is speculated that the reproductive risk associated with exposure to endogenous or exogenous chemicals may be modified by genetic variation in metabolic detoxification activities. The cytochrome P450 CYP1A1 and CYP1A2 is of major interest due to its ability to metabolize both endogenous and exogenous compounds. The purpose of this study was to identify associations or interrelations between carriage of the CYP1A1 (MspI) and CYP1A2 (ApaI) polymorphisms and congenital abnormalities of fetal development (CA) or recurrent miscarriage (RM) in patients living in an ecologically unfavourable with the increased level of harmful pollutions. We studied women with a history of two or three consecutive pregnancy losses before 15 weeks gestation (RM group; 118 and 120 for CYP1A1 and CYP1A2 respectively), women with a history of congenital abnormalities of fetal development (CA group; 80 and 81 for CYP1A1 and CYP1A2 respectively), and 100 healthy pregnant women with at least one live birth and no history of pregnancy loss. Peripheral venous puncture, DNA extraction and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were employed in genotyping analysis. Allele and genotype frequencies of all polymorphisms were not significantly different between the studied and control groups. Also, no significant association occurred between combinations of polymorphisms and the occurrence of CA and RM. In conclusion, our data fall short of showing any significant association between single polymorphisms of the CYP1A1 (MspI) and CYP1A2 (ApaI) genes or combinations of these polymorphisms and the occurrence of CA and RM. To analyze the gene expression data, we used various bioinformatic software. Hierarchical clustering methods were used to group genes and samples with similar expression in an unsupervised mode (Cluster&Treeview software). Genes of known function were further sorted in a supervised way by enzyme, function and pathway clusters using Gemtools software (IncyteGenomics). Taken together, these data defined molecular fingerprints of human MPM with more than 700 up-and down-regulated genes related to several traits of the malignant phenotype, specially associated with MPM invasiveness, protection and resistance to anticancer defenses. This portrait is meaningful in disease classification and relevant to find new specific markers of MPM. Such molecular markers should improve the accuracy of mesothelioma diagnosis, prognosis and therapy. The products of genes of bone tissue metabolism take part in forming of definite physical status of the organism. The most intensive studies deal with the definition of the rate of association between vitamin D receptor gene (VDR) variants and bone mineral density, and also between alleles of calcitonin receptor gene (CALCR), collagen type 1 gene polymorphism (Col1a1) with mass and strength of bone. The allele rates of VDR, Col1a1 and CALCR genes in 59 nonrelated men from Northwest Russian population and in 57 athletes (rowers) from Saint Petersburg were investigated. The polymorphisms of VDR, Col1a1 and CALCR genes were studied by PCR-RFLP method. The frequency of allele t (VDR gene) in the group of rowers was 40.4%. It was significantly higher (p<0,01) than in population group (28.7%). The frequency of tt genotype was higher in the group of rowers (19.3%) compared with the population group (9.3%). Analysis of the Col1a1 gene did not reveal significant differences (p>0,05) of the genotype's frequencies in studied groups (rowers -SS-77.2%, Ss-19.3%, ss-3.5%; population -SS-77.2%, Ss-22.8%, ss-0.0%). The frequency of allele s in the group of rowers was 13.2% and did not differ significantly (p>0,05) from the average in the population group (11.4%). The CALCR gene was investigated also. We have found significant differences (p<0,01) of the frequencies of genotypes for this polymorphism in two studied groups (rowers -TT-70.2%, TC-17.5%, CC-12.3%; population -TT-54.2%, TC-33.9%, CC-11.9%). The frequency of allele T in the group of rowers was 78.9% and did not differ significantly (p>0,05) from the average in population (71.2%).
CYP1A1 and CYP1A2 Genetic
Microarray Gene Expression Profiling in Human Mesothelioma
The results suggest that the athletes have tt (VDR), TT (CALCR) genotypes may be more successful in sport. Accordingly our findings perspectives and predictable expediency of using genetic predisposition analysis as one of the basic method in formation of Olympic and other teams are under discussion. Russian President's Medical Centre, Moscow, Russia
To study the genetic predisposition to coronary artery disease (CAD) in Russian patients we used polymorphic markers C677T and A1298C of MTHFR gene and C825T of GNB3 gene. Two groups of patients have been formed: group with acute unstable angina (n=216) and control group (n=115) in which all patients had no clinical CAD. Allele identification of polymorphic markers was performed using PCR, restriction endonuclease cleavages and separation in 8% polyacrylamide gel. We have not found significant association with CAD in case of C677T marker of MTHFR gene. However another marker A1298C of this gene showed a significant association with CAD. The carriers of A allele and AA genotype had lower risk (OR = 0.41 and 0.59, relatively; p < 0.05), whereas the carriers of C allele and CC genotype had higher risk of CAD (OR = 1.68 and 2.41, relatively; p < 0.035). High levels of plasma total homocysteine have been suggested to involve in arterial or venous occlusive diseases. Our findings correlate with data of Chango et al (Br. J. Nutr. 83, (593) (594) (595) (596) . These authors showed that the carriers of CC genotype had significantly lower MTHFR specific activity and higher level of plasma total homocysteine. In case of C825T polymorphic marker of GNB3 gene we found that the carriers of T allele, CT and TT genotype had lower risk (OR = 0.42, 0.41 and 0.45, relatively; p < 0.0001), whereas the carriers of C allele and CC genotype had higher risk of CAD (OR = 2.37 and 3.11, relatively; p < 0.0001). GNB3 gene encodes the ubiquitously expressed beta3 subunit of heterotrimeric G proteins. The 825T allele is associated with alternative splicing of the gene and enhanced signal transduction via G proteins. We can conclude that the polymorphic markers A1298C of MTHFR and C825T of GNB3 genes have shown a strong association with coronary artery disease among Russians of Moscow city. A raised plasma factor VII (FVII) level is one of risk factors for coronary artery disease. DNA variants have been described to be associated with alteration in FVII levels [1] . The presence of FVII polymorphism is unknown in the Tunisian Arabic population. In a group of 240 healthy Tunisians, we examined the relationship between levels of FVII coagulant activity (FVIIc) and two polymorphisms in the FVII gene. One polymorphism alters arginine at position 353 to glutamine (R/Q) and the other one is a 10 base pair insertion (0/10). The FVII distribution was in accordance with Hardy-Weinberg equilibrium. The allele frequencies of Q and 10 bp were 0.212 and 0.235, respectively. Our results revealed significant differences in these allelic frequencies between Tunisian and other populations [2] (p < 0.001). We observed lower FVIIc among subjects with the Q allele compared to RR subjects (RR: 98.17%, RQ/QQ: 57.41%, p < 0.0001). The prevalence of the Q allele which was found to be associated with lower plasma FVIIc levels is high in Tunisian Arab population. Further analyses should yielded information on the protective role of carrying the Q allele for coronary artery disease.
Peptidomic Analysis of Plasma Samples After Oral Administration of Glucose
Tammen H., Schulte I., Kellmann M., Jurgens M., Hess R., Schulz-Knappe P.* BioVisioN AG, Feodor-Lynen-Str 5. 30625 Hannover, Germany Mass spectrometric plasma analysis has become an exploratory focus in proteomic research over the last years. Not only since the human proteome organization (HUPO) has emphasis on the human plasma proteome, the challenges of analyzing plasma samples by mass spectrometry have become apparent. Due to the complex biological matrix of plasma and interindividual variations as well as low concentration of putative biomarkers the proteomic analysis of plasma is difficult. Differential Peptide Display (DPD) is a technique for peptidomics studies to compare comprehensive peptide displays from distinct biological samples. Peptides are extracted from samples, the extracts were separated by liquid chromatography and each collected fraction was subjected to mass spectrometry. Mass spectra of all fractions were combined resulting in a two-dimensional display of peptide masses [1] . This work demonstrates fundamental proteomic research to reveal sensivity of our approach by spiking plama samples with picomolar concentrations of peptides and by distinct changes in plasma peptide composition in samples after challenging individuals with orally administrated glucose. The different peptide concentrations before and after oral administration of glucose were detected in plasma samples by DPD and their sequence was identified by nESI-qTOF mass spectrometry. Landmark peptides such as Insulin (mean value: 150 pM post oGTT, by ELISA) and C-peptide (mean value: 500 pM pre oGTT, 1,5 nM post oGTT, by ELISA) were detected in the peptide displays and shown to correlate well with ELISA measurements. The study serves as a proof of principle for successful proteomic biomarker discovery by using peptidomics technologies. The challenges over the next years in proteomic plasma research is to enhance the detection limit down to the low picomolar range to permit the detection of relevant biomarkers in the context of specific diseases. 
Relation between Vitamin
